<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="chapter-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">978-981-15-0810-3</journal-id>
<journal-id journal-id-type="doi">10.1007/978-981-15-0810-3</journal-id>
<journal-id journal-id-type="nlm-ta">PET/CT for Inflammatory Diseases</journal-id>
<journal-title-group>
<journal-title>PET/CT for Inflammatory Diseases</journal-title>
<journal-subtitle>Basic Sciences, Typical Cases, and Review</journal-subtitle>
</journal-title-group>
<isbn publication-format="print">978-981-15-0809-7</isbn>
<isbn publication-format="electronic">978-981-15-0810-3</isbn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmc">7418531</article-id>
<article-id pub-id-type="publisher-id">1</article-id>
<article-id pub-id-type="doi">10.1007/978-981-15-0810-3_1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Basic Science of PET Imaging for Inflammatory Diseases</article-title>
</title-group>
<contrib-group content-type="book editors">
<contrib contrib-type="editor">
<name>
<surname>Toyama</surname>
<given-names>Hiroshi</given-names>
</name>
<address>
<email>htoyama@fujita-hu.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Li</surname>
<given-names>Yaming</given-names>
</name>
<address>
<email>ymli2001@163.com</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Hatazawa</surname>
<given-names>Jun</given-names>
</name>
<address>
<email>hatazawa@tracer.med.osaka-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Huang</surname>
<given-names>Guang</given-names>
</name>
<address>
<email>huang2802@163.com</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Kubota</surname>
<given-names>Kazuo</given-names>
</name>
<address>
<email>kkubota@cpost.plala.or.jp</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.256115.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 798X</institution-id><institution>Department of Radiology, </institution><institution>Fujita Health University, </institution></institution-wrap>Toyoake, Aichi Japan </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412636.4</institution-id><institution>Department of Nuclear Medicine, </institution><institution>The First Hospital of China Medical University, </institution></institution-wrap>Shenyang, Liaoning China </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Joint Research Division for the Quantum Cancer Therapy, Research Center for Nuclear Physics, </institution><institution>Professor Emeritus, Osaka University, </institution></institution-wrap>Suita, Osaka Japan </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.39436.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2323 5732</institution-id><institution>Shanghai University of Medicine &amp; Health Sciences, </institution></institution-wrap>Shanghai, China </aff>
<aff id="Aff5"><label>5</label>Department of Radiology, Southern TOHOKU General Hospital, Koriyama, Fukushima Japan </aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kubota</surname>
<given-names>Kazuo</given-names>
</name>
<address>
<email>kkubota@cpost.plala.or.jp</email>
</address>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ogawa</surname>
<given-names>Mikako</given-names>
</name>
<address>
<email>mogawa@pharm.hokudai.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Bin</given-names>
</name>
<address>
<email>Ji.bin@qst.go.jp</email>
</address>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Watabe</surname>
<given-names>Tadashi</given-names>
</name>
<address>
<email>watabe@tracer.med.osaka-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Ming-Rong</given-names>
</name>
<address>
<email>zhang.ming-rong@qst.go.jp</email>
</address>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suzuki</surname>
<given-names>Hiromi</given-names>
</name>
<address>
<email>hiromi_s@riem.nagoya-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sawada</surname>
<given-names>Makoto</given-names>
</name>
<address>
<email>msawada@riem.nagoya-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nishi</surname>
<given-names>Kodai</given-names>
</name>
<address>
<email>koudai@nagasaki-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kudo</surname>
<given-names>Takashi</given-names>
</name>
<address>
<email>tkudo123@nagasaki-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<aff id="Aff6"><label>6</label>Department of Radiology, Southern TOHOKU General Hospital, Koriyama, Fukushima Japan </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.39158.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2173 7691</institution-id><institution>Laboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, </institution><institution>Hokkaido University, </institution></institution-wrap>Sapporo, Hokkaido Japan </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.482503.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 5900 003X</institution-id><institution>Department of Functional Brain Imaging Research (DOFI), National Institute of Radiological Sciences, </institution><institution>National Institutes for Quantum and Radiological Science and Technology, </institution></institution-wrap>Chiba, Japan </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Department of Nuclear Medicine and Tracer Kinetics, </institution><institution>Osaka University Graduate School of Medicine, </institution></institution-wrap>Osaka, Japan </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.482503.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 5900 003X</institution-id><institution>Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, </institution><institution>National Institutes for Quantum and Radiological Science and Technology, </institution></institution-wrap>Chiba, Japan </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution>Division of Stress Adaptation and Protection, Department of Brain Function, Research Institute of Environmental Medicine, </institution><institution>Nagoya University, </institution></institution-wrap>Nagoya, Aichi Japan </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.174567.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 8902 2273</institution-id><institution>Department of Radioisotope Medicine, Atomic Bomb Disease Institute, </institution><institution>Nagasaki University, </institution></institution-wrap>Nagasaki, Japan </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>12</month>
<year>2019</year>
</pub-date>
<fpage>1</fpage>
<lpage>42</lpage>
<permissions>
<copyright-statement>Â© Springer Nature Singapore Pte Ltd. 2020</copyright-statement>
<license>
<license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">FDG-PET/CT has recently emerged as a useful tool for the evaluation of inflammatory diseases too, in addition to that of malignant diseases. The imaging is based on active glucose utilization by inflammatory tissue. Autoradiography studies have demonstrated high FDG uptake in macrophages, granulocytes, fibroblasts, and granulation tissue. Especially, activated macrophages are responsible for the elevated FDG uptake in some types of inflammation. According to one study, after activation by lipopolysaccharide of cultured macrophages, the [<sup>14</sup>C]2DG uptake by the cells doubled, reaching the level seen in glioblastoma cells. In activated macrophages, increase in the expression of total GLUT1 and redistributions from the intracellular compartments toward the cell surface have been reported. In one rheumatoid arthritis model, following stimulation by hypoxia or TNF-Î±, the highest elevation of the [<sup>3</sup>H]FDG uptake was observed in the fibroblasts, followed by that in macrophages and neutrophils. As the fundamental mechanism of elevated glucose uptake in both cancer cells and inflammatory cells, activation of glucose metabolism as an adaptive response to a hypoxic environment has been reported, with transcription factor HIF-1Î± playing a key role. Inflammatory cells and cancer cells seem to share the same molecular mechanism of elevated glucose metabolism, lending support to the notion of usefulness of FDGPET/CT for the evaluation of inflammatory diseases, besides cancer.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>Â© Springer Nature Singapore Pte Ltd. 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<back>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology</article-title>
<source/>Ann Nucl Med
          <year>2001</year>
<volume>15</volume>
<fpage>471</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1007/BF02988499</pub-id>
<pub-id pub-id-type="pmid">11831394</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Djulbegovic</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>HP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recommendations on the use of 18F-FDG PET in oncology</article-title>
<source/>J Nucl Med
          <year>2008</year>
<volume>49</volume>
<fpage>480</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.107.047787</pub-id>
<pub-id pub-id-type="pmid">18287273</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boellaard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Delgado-Bolton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Oyen</surname>
<given-names>WJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2015</year>
<volume>42</volume>
<fpage>328</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-014-2961-x</pub-id>
<pub-id pub-id-type="pmid">25452219</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ichiya</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kuwabara</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High [18F]fluorodeoxyglucose uptake in abdominal abscess: a PET study</article-title>
<source/>J Comput Assist Tomogr
          <year>1989</year>
<volume>13</volume>
<fpage>829</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="doi">10.1097/00004728-198909000-00014</pub-id>
<pub-id pub-id-type="pmid">2789238</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ichiya</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kuwabara</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ring-like uptake of [18F]FDG in brain abscess: a PET study</article-title>
<source/>J Comput Assist Tomogr
          <year>1990</year>
<volume>14</volume>
<fpage>486</fpage>
<lpage>487</lpage>
<pub-id pub-id-type="pmid">2335626</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsuzawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential diagnosis of lung tumor with positron emission tomography: a prospective study</article-title>
<source/>J Nucl Med
          <year>1990</year>
<volume>31</volume>
<fpage>1927</fpage>
<lpage>1933</lpage>
<pub-id pub-id-type="pmid">2266388</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intratumoral distribution of fluorine-18-fluorodeosxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography</article-title>
<source/>J Nucl Med
          <year>1992</year>
<volume>33</volume>
<fpage>1972</fpage>
<lpage>1980</lpage>
<pub-id pub-id-type="pmid">1432158</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>FDG accumulation in tumor tissue</article-title>
<source/>J Nucl Med
          <year>1993</year>
<volume>34</volume>
<fpage>75</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">8418275</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue</article-title>
<source/>J Nucl Med
          <year>1995</year>
<volume>36</volume>
<fpage>1301</fpage>
<lpage>1306</lpage>
<pub-id pub-id-type="pmid">7790960</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mochizuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tsukamoto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kuge</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models</article-title>
<source/>J Nucl Med
          <year>2001</year>
<volume>42</volume>
<fpage>1551</fpage>
<lpage>1555</lpage>
<pub-id pub-id-type="pmid">11585872</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kuge</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Masashi Kohanawa</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Usefulness of 11C-Methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT</article-title>
<source/>J Nucl Med
          <year>2008</year>
<volume>49</volume>
<fpage>135</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.107.044578</pub-id>
<pub-id pub-id-type="pmid">18077525</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deichen</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Prante</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gack</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro</article-title>
<source/>Eur J Nucl Med
          <year>2003</year>
<volume>30</volume>
<fpage>267</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-002-1018-8</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malide</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Davies-Hill</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation</article-title>
<source/>Am J Phys
          <year>1998</year>
<volume>274</volume>
<issue>3</issue>
<fpage>E516</fpage>
<lpage>E526</lpage>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Cadwallader</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of 18F-FDG PET images</article-title>
<source/>J Nucl Med
          <year>2002</year>
<volume>43</volume>
<fpage>652</fpage>
<lpage>657</lpage>
<pub-id pub-id-type="pmid">11994530</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishimori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saga</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mameda</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased 18F-FDG uptake in a model of inflammation: Concanavalin Aâmediated lymphocyte activation</article-title>
<source/>J Nucl Med
          <year>2002</year>
<volume>43</volume>
<fpage>658</fpage>
<lpage>663</lpage>
<pub-id pub-id-type="pmid">11994531</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Weinblatt</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Rheumatoid arthritis</article-title>
<source/>Lancet
          <year>2001</year>
<volume>358</volume>
<fpage>903</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(01)06075-5</pub-id>
<pub-id pub-id-type="pmid">11567728</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis</article-title>
<source/>J Nucl Med
          <year>2009</year>
<volume>50</volume>
<fpage>920</fpage>
<lpage>926</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.108.060103</pub-id>
<pub-id pub-id-type="pmid">19443596</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roiniotis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dinh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Masendycz</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypoxia prolongs monocyte/macrophage survival and enhanced glycolysis is associated with their maturation under aerobic conditions</article-title>
<source/>J Immunol
          <year>2009</year>
<volume>182</volume>
<fpage>7974</fpage>
<lpage>7981</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0804216</pub-id>
<pub-id pub-id-type="pmid">19494322</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Carbonell</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Divakaruni</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Lodi</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes</article-title>
<source/>Arthritis Rheumatol
          <year>2016</year>
<volume>68</volume>
<fpage>1614</fpage>
<lpage>1626</lpage>
<pub-id pub-id-type="doi">10.1002/art.39608</pub-id>
<pub-id pub-id-type="pmid">26815411</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamanishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Clausen</surname>
<given-names>BE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HIF-1Î± is essential for myeloid cell-mediated inflammation</article-title>
<source/>Cell
          <year>2003</year>
<volume>112</volume>
<fpage>645</fpage>
<lpage>657</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(03)00154-5</pub-id>
<pub-id pub-id-type="pmid">12628185</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denko</surname>
<given-names>NC</given-names>
</name>
</person-group>
<article-title>Hypoxia, HIF1 and glucose metabolism in the solid tumour</article-title>
<source/>Nat Rev Cancer
          <year>2008</year>
<volume>8</volume>
<fpage>705</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2468</pub-id>
<pub-id pub-id-type="pmid">19143055</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Buscombe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chiti</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>EANM/SNMI guideline for 18F-FDG use in inflammation and infection</article-title>
<source/>J Nucl Med
          <year>2013</year>
<volume>54</volume>
<fpage>647</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.112.112524</pub-id>
<pub-id pub-id-type="pmid">23359660</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lendon</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Born</surname>
<given-names>GV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Atherosclerotic plaque caps are locally weakened when macrophages density is increased</article-title>
<source/>Atherosclerosis
          <year>1991</year>
<volume>87</volume>
<fpage>87</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/0021-9150(91)90235-U</pub-id>
<pub-id pub-id-type="pmid">1872926</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacNeill</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Bouma</surname>
<given-names>BE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease</article-title>
<source/>J Am Coll Cardiol
          <year>2004</year>
<volume>44</volume>
<fpage>972</fpage>
<lpage>979</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2004.05.066</pub-id>
<pub-id pub-id-type="pmid">15337206</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake</article-title>
<source/>J Nucl Med
          <year>1994</year>
<volume>35</volume>
<fpage>104</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="pmid">8271030</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatsumi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cohade</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nakamoto</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis</article-title>
<source/>Radiology
          <year>2003</year>
<volume>229</volume>
<fpage>831</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1148/radiol.2293021168</pub-id>
<pub-id pub-id-type="pmid">14593193</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudd</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Warburton</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>TD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography</article-title>
<source/>Circulation
          <year>2002</year>
<volume>105</volume>
<fpage>2708</fpage>
<lpage>2711</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.0000020548.60110.76</pub-id>
<pub-id pub-id-type="pmid">12057982</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cucchiara</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors</article-title>
<source/>Semin Nucl Med
          <year>2002</year>
<volume>32</volume>
<fpage>70</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1053/snuc.2002.29279</pub-id>
<pub-id pub-id-type="pmid">11839072</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mukai</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study</article-title>
<source/>J Nucl Med
          <year>2004</year>
<volume>45</volume>
<fpage>1245</fpage>
<lpage>1250</lpage>
<pub-id pub-id-type="pmid">15235073</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graebe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Borgwardt</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET)</article-title>
<source/>Eur J Vasc Endovasc Surg
          <year>2009</year>
<volume>37</volume>
<fpage>714</fpage>
<lpage>721</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejvs.2008.11.018</pub-id>
<pub-id pub-id-type="pmid">19112034</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tawakol</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Migrino</surname>
<given-names>RQ</given-names>
</name>
<name>
<surname>Bashian</surname>
<given-names>GG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients</article-title>
<source/>J Am Coll Cardiol
          <year>2006</year>
<volume>48</volume>
<fpage>1818</fpage>
<lpage>1824</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2006.05.076</pub-id>
<pub-id pub-id-type="pmid">17084256</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1</article-title>
<source/>J Nucl Med
          <year>2007</year>
<volume>48</volume>
<fpage>227</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="pmid">17268019</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamagishi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome</article-title>
<source/>J Am Coll Cardiol
          <year>2007</year>
<volume>49</volume>
<fpage>1533</fpage>
<lpage>1539</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2006.11.046</pub-id>
<pub-id pub-id-type="pmid">17418291</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skeoch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cristinacce</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-fluorodeoxyglucose PET-CT and MRI: a pilot study</article-title>
<source/>Lancet
          <year>2015</year>
<volume>385</volume>
<issue>Suppl 1</issue>
<fpage>S91</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(15)60406-8</pub-id>
<pub-id pub-id-type="pmid">26312914</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro</article-title>
<source/>J Nucl Med
          <year>2012</year>
<volume>53</volume>
<fpage>55</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.111.092866</pub-id>
<pub-id pub-id-type="pmid">22128324</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>18F-FDG PET and intravascular ultrasonography (IVUS) images compared with histology of atherosclerotic plaques: 18F-FDG accumulates in foamy macrophages</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2014</year>
<volume>41</volume>
<fpage>624</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-013-2635-0</pub-id>
<pub-id pub-id-type="pmid">24258009</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chinetti-Gbaguidi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Staels</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Macrophage phenotypes in atherosclerosis</article-title>
<source/>Immunol Rev
          <year>2014</year>
<volume>262</volume>
<fpage>153</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1111/imr.12218</pub-id>
<pub-id pub-id-type="pmid">25319333</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garlanda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Locati</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Macrophage diversity and polarization in atherosclerosis: a question of balance</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2009</year>
<volume>29</volume>
<fpage>1419</fpage>
<lpage>1423</lpage>
<pub-id pub-id-type="doi">10.1161/ATVBAHA.108.180497</pub-id>
<pub-id pub-id-type="pmid">19696407</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satomi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide</article-title>
<source/>J Nucl Med
          <year>2013</year>
<volume>54</volume>
<fpage>999</fpage>
<lpage>1004</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.112.110551</pub-id>
<pub-id pub-id-type="pmid">23670898</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiomi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirouchi</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins</article-title>
<source/>Atherosclerosis
          <year>2001</year>
<volume>157</volume>
<fpage>75</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/S0021-9150(00)00708-5</pub-id>
<pub-id pub-id-type="pmid">11427206</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukumoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Libby</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rabkin</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits</article-title>
<source/>Circulation
          <year>2001</year>
<volume>103</volume>
<fpage>993</fpage>
<lpage>999</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.103.7.993</pub-id>
<pub-id pub-id-type="pmid">11181475</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daugherty</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zweifel</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Schonfeld</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits</article-title>
<source/>Br J Pharmacol
          <year>1991</year>
<volume>103</volume>
<fpage>1013</fpage>
<lpage>1018</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.1991.tb12293.x</pub-id>
<pub-id pub-id-type="pmid">1878742</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parthasarathy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carew</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>In vivo inhibition of foam cell development by probucol in Watanabe rabbits</article-title>
<source/>Am J Cardiol
          <year>1988</year>
<volume>62</volume>
<fpage>6B</fpage>
<lpage>12B</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9149(88)80044-4</pub-id>
<pub-id pub-id-type="pmid">3394654</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques</article-title>
<source/>J Nucl Med
          <year>2006</year>
<volume>47</volume>
<fpage>1845</fpage>
<lpage>1850</lpage>
<pub-id pub-id-type="pmid">17079818</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pirro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Simental-Mendia</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bianconi</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET/CT: a systematic review and meta-analysis of interventional studies</article-title>
<source/>J Clin Med
          <year>2019</year>
<volume>8</volume>
<fpage>118</fpage>
<pub-id pub-id-type="doi">10.3390/jcm8010118</pub-id>
<pub-id pub-id-type="pmid">6352284</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghbel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Al-Zaghal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>TJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of PET in evaluating atherosclerosis: a critical review</article-title>
<source/>Semin Nucl Med
          <year>2018</year>
<volume>48</volume>
<fpage>488</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="doi">10.1053/j.semnuclmed.2018.07.001</pub-id>
<pub-id pub-id-type="pmid">30322475</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<mixed-citation publication-type="other">Mehta NN, Torigian DA, Gelfand JM, et al. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;63:e3777.</mixed-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2012</year>
<volume>39</volume>
<fpage>399</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-011-1994-7</pub-id>
<pub-id pub-id-type="pmid">22109668</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishii</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nishio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention</article-title>
<source/>Clin Ther
          <year>2010</year>
<volume>32</volume>
<fpage>2337</fpage>
<lpage>2347</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinthera.2010.12.001</pub-id>
<pub-id pub-id-type="pmid">21353104</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography</article-title>
<source/>J Am Coll Cardiol
          <year>2006</year>
<volume>48</volume>
<fpage>1825</fpage>
<lpage>1831</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2006.03.069</pub-id>
<pub-id pub-id-type="pmid">17084257</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fayad</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Woodward</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial</article-title>
<source/>Lancet
          <year>2011</year>
<volume>378</volume>
<fpage>1547</fpage>
<lpage>1559</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(11)61383-4</pub-id>
<pub-id pub-id-type="pmid">21908036</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duivenvoorden</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Woodward</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study</article-title>
<source/>JACC Cardiovasc Imaging
          <year>2013</year>
<volume>6</volume>
<fpage>1087</fpage>
<lpage>1094</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcmg.2013.03.009</pub-id>
<pub-id pub-id-type="pmid">24135322</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hellberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Silvola</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kiugel</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Type 2 diabetes enhances arterial uptake of choline in atherosclerotic mice: an imaging study with positron emission tomography tracer (1)(8)F-fluoromethylcholine</article-title>
<source/>Cardiovasc Diabetol
          <year>2016</year>
<volume>15</volume>
<fpage>26</fpage>
<pub-id pub-id-type="doi">10.1186/s12933-016-0340-6</pub-id>
<pub-id pub-id-type="pmid">26852231</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schober</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2009</year>
<volume>36</volume>
<fpage>1622</fpage>
<lpage>1628</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-009-1152-7</pub-id>
<pub-id pub-id-type="pmid">19430785</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ammirati</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Magnoni</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Carotid artery plaque uptake of (11)C-PK11195 inversely correlates with circulating monocytes and classical CD14(++)CD16(â) monocytes expressing HLA-DR</article-title>
<source/>Int J Cardiol Heart Vasc
          <year>2018</year>
<volume>21</volume>
<fpage>32</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">30276231</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaemperli</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Shalhoub</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>DR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography</article-title>
<source/>Eur Heart J
          <year>2012</year>
<volume>33</volume>
<fpage>1902</fpage>
<lpage>1910</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehr367</pub-id>
<pub-id pub-id-type="pmid">21933781</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Paeng</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Measurement of (68)Ga-DOTATOC uptake in the thoracic aorta and its correlation with cardiovascular risk</article-title>
<source/>Nucl Med Mol Imaging
          <year>2018</year>
<volume>52</volume>
<fpage>279</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1007/s13139-018-0524-y</pub-id>
<pub-id pub-id-type="pmid">30100940</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malmberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ripa</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Johnbeck</surname>
<given-names>CB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with 68Ga-DOTATOC in 60 patients</article-title>
<source/>J Nucl Med
          <year>2015</year>
<volume>56</volume>
<fpage>1895</fpage>
<lpage>1900</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.115.161216</pub-id>
<pub-id pub-id-type="pmid">26429961</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mateo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Izquierdo-Garcia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Badimon</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using (1)(8)F-fluoromisonidazole positron emission tomographic imaging</article-title>
<source/>Circ Cardiovasc Imaging
          <year>2014</year>
<volume>7</volume>
<fpage>312</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCIMAGING.113.001084</pub-id>
<pub-id pub-id-type="pmid">24508668</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Macapinlac</surname>
<given-names>HA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Correlation of fluorine 18-labeled sodium fluoride uptake and arterial calcification on whole-body PET/CT in cancer patients</article-title>
<source/>Nucl Med Commun
          <year>2019</year>
<volume>40</volume>
<fpage>604</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1097/MNM.0000000000000986</pub-id>
<pub-id pub-id-type="pmid">30688757</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitagawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakamoto</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Predictive value of (18)F-sodium fluoride positron emission tomography in detecting high-risk coronary artery disease in combination with computed tomography</article-title>
<source/>J Am Heart Assoc
          <year>2018</year>
<volume>7</volume>
<fpage>e010224</fpage>
<pub-id pub-id-type="doi">10.1161/JAHA.118.010224</pub-id>
<pub-id pub-id-type="pmid">30371290</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellinge</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Majeed</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In search of the vulnerable patient or the vulnerable plaque: (18)F-sodium fluoride positron emission tomography for cardiovascular risk stratification</article-title>
<source/>J Nucl Cardiol
          <year>2018</year>
<volume>25</volume>
<fpage>1774</fpage>
<lpage>1783</lpage>
<pub-id pub-id-type="doi">10.1007/s12350-018-1360-2</pub-id>
<pub-id pub-id-type="pmid">29992525</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitagawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toshimitsu</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(18)F-sodium fluoride positron emission tomography for molecular imaging of coronary atherosclerosis based on computed tomography analysis</article-title>
<source/>Atherosclerosis
          <year>2017</year>
<volume>263</volume>
<fpage>385</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2017.04.024</pub-id>
<pub-id pub-id-type="pmid">28528743</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hellberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Silvola</surname>
<given-names>JMU</given-names>
</name>
<name>
<surname>Liljenback</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Amyloid-targeting PET tracer [(18)F]Flutemetamol accumulates in atherosclerotic plaques</article-title>
<source/>Molecules
          <year>2019</year>
<volume>24</volume>
<fpage>1072</fpage>
<pub-id pub-id-type="doi">10.3390/molecules24061072</pub-id>
<pub-id pub-id-type="pmid">6471324</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenney-Drake</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Moghbel</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Paydary</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(18)F-NaF and (18)F-FDG as molecular probes in the evaluation of atherosclerosis</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2018</year>
<volume>45</volume>
<fpage>2190</fpage>
<lpage>2200</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-018-4078-0</pub-id>
<pub-id pub-id-type="pmid">29978245</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Heber</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cal-Gonzalez</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between osteogenesis and inflammation during the progression of calcified plaque evaluated by (18)F-fluoride and (18)F-FDG</article-title>
<source/>J Nucl Med
          <year>2017</year>
<volume>58</volume>
<fpage>968</fpage>
<lpage>974</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.116.182790</pub-id>
<pub-id pub-id-type="pmid">28232606</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quirce</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Martinez-Rodriguez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Banzo</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>New insight of functional molecular imaging into the atheroma biology: 18F-NaF and 18F-FDG in symptomatic and asymptomatic carotid plaques after recent CVA. Preliminary results</article-title>
<source/>Clin Physiol Funct Imaging
          <year>2016</year>
<volume>36</volume>
<fpage>499</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1111/cpf.12254</pub-id>
<pub-id pub-id-type="pmid">26147617</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishiwata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kaneta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nawata</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantification of temporal changes in calcium score in active atherosclerotic plaque in major vessels by (18)F-sodium fluoride PET/CT</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2017</year>
<volume>44</volume>
<fpage>1529</fpage>
<lpage>1537</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-017-3680-x</pub-id>
<pub-id pub-id-type="pmid">28349280</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irkle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vesey</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography</article-title>
<source/>Nat Commun
          <year>2015</year>
<volume>6</volume>
<fpage>7495</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms8495</pub-id>
<pub-id pub-id-type="pmid">26151378</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alam</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
</person-group>
<article-title>Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurological diseases</article-title>
<source/>Nucl Med Mol Imaging
          <year>2017</year>
<volume>51</volume>
<issue>4</issue>
<fpage>283</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1007/s13139-017-0475-8</pub-id>
<pub-id pub-id-type="pmid">29242722</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Truillet</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Longitudinal imaging of microglia-astrocyte activation in mouse mesial temporal lobe epilepsy with TSPO PET to identify the best therapeutic time windows</article-title>
<source/>MÃ©decine NuclÃ©aire
          <year>2018</year>
<volume>42</volume>
<issue>3</issue>
<fpage>179</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1016/j.mednuc.2018.03.123</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimerâs disease and related disorders</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<issue>12</issue>
<fpage>4720</fpage>
<lpage>4730</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3076-10.2011</pub-id>
<pub-id pub-id-type="pmid">21430171</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupont</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases</article-title>
<source/>Int J Mol Sci
          <year>2017</year>
<volume>18</volume>
<issue>4</issue>
<fpage>E785</fpage>
<pub-id pub-id-type="doi">10.3390/ijms18040785</pub-id>
<pub-id pub-id-type="pmid">28387722</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<issue>47</issue>
<fpage>12255</fpage>
<lpage>12267</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2312-08.2008</pub-id>
<pub-id pub-id-type="pmid">19020019</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct binding of amyloid imaging ligands to unique amyloid-beta deposited in the presubiculum of Alzheimerâs disease</article-title>
<source/>J Neurochem
          <year>2015</year>
<volume>135</volume>
<issue>5</issue>
<fpage>859</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13293</pub-id>
<pub-id pub-id-type="pmid">26315807</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo visualization of tau accumulation, microglial activation, and brain atrophy in a mouse model of tauopathy rTg4510</article-title>
<source/>J Alzheimers Dis
          <year>2018</year>
<volume>61</volume>
<issue>3</issue>
<fpage>1037</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-170509</pub-id>
<pub-id pub-id-type="pmid">29332041</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimerâs disease enabled by positron emission tomography</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<issue>41</issue>
<fpage>10957</fpage>
<lpage>10968</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0673-07.2007</pub-id>
<pub-id pub-id-type="pmid">17928437</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparative in vitro and in vivo quantifications of pathologic tau deposits and their association with neurodegeneration in tauopathy mouse models</article-title>
<source/>J Nucl Med
          <year>2018</year>
<volume>59</volume>
<issue>6</issue>
<fpage>960</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.117.201632</pub-id>
<pub-id pub-id-type="pmid">29419480</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gargiulo</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2016</year>
<volume>43</volume>
<issue>7</issue>
<fpage>1348</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-016-3311-y</pub-id>
<pub-id pub-id-type="pmid">26816193</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>MD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>[11C]PBR28 PET imaging is sensitive to neuroinflammation in the aged rat</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2015</year>
<volume>35</volume>
<issue>8</issue>
<fpage>1331</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2015.54</pub-id>
<pub-id pub-id-type="pmid">25833342</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerhard</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>TSPO imaging in parkinsonian disorders</article-title>
<source/>Clin Transl Imaging
          <year>2016</year>
<volume>4</volume>
<fpage>183</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1007/s40336-016-0171-1</pub-id>
<pub-id pub-id-type="pmid">27340650</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varnas</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PET imaging of [(11)C]PBR28 in Parkinsonâs disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2019</year>
<volume>46</volume>
<issue>2</issue>
<fpage>367</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-018-4161-6</pub-id>
<pub-id pub-id-type="pmid">30270409</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrice</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gregory-Evans</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Animal models of amyotrophic lateral sclerosis: a comparison of model validity</article-title>
<source/>Neural Regen Res
          <year>2018</year>
<volume>13</volume>
<issue>12</issue>
<fpage>2050</fpage>
<lpage>2054</lpage>
<pub-id pub-id-type="doi">10.4103/1673-5374.241445</pub-id>
<pub-id pub-id-type="pmid">30323119</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankowsky</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Practical considerations for choosing a mouse model of Alzheimerâs disease</article-title>
<source/>Mol Neurodegener
          <year>2017</year>
<volume>12</volume>
<issue>1</issue>
<fpage>89</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-017-0231-7</pub-id>
<pub-id pub-id-type="pmid">29273078</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>DR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2012</year>
<volume>32</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2011.147</pub-id>
<pub-id pub-id-type="pmid">22008728</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzo</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2014</year>
<volume>34</volume>
<issue>6</issue>
<fpage>1060</fpage>
<lpage>1069</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2014.55</pub-id>
<pub-id pub-id-type="pmid">24667911</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomasi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimerâs disease</article-title>
<source/>J Nucl Med
          <year>2008</year>
<volume>49</volume>
<issue>8</issue>
<fpage>1249</fpage>
<lpage>1256</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.108.050583</pub-id>
<pub-id pub-id-type="pmid">18632810</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horti</surname>
<given-names>AG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R)</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2019</year>
<volume>116</volume>
<issue>5</issue>
<fpage>1686</fpage>
<lpage>1691</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1812155116</pub-id>
<pub-id pub-id-type="pmid">30635412</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanzey</surname>
<given-names>SS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synthesis and initial in vivo evaluation of [(11)C]AZ683âa novel PET radiotracer for colony stimulating factor 1 receptor (CSF1R)</article-title>
<source/>Pharmaceuticals (Basel)
          <year>2018</year>
<volume>11</volume>
<issue>4</issue>
<fpage>136</fpage>
<pub-id pub-id-type="doi">10.3390/ph11040136</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaino</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis</article-title>
<source/>J Neuroinflammation
          <year>2017</year>
<volume>14</volume>
<issue>1</issue>
<fpage>259</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-017-1034-z</pub-id>
<pub-id pub-id-type="pmid">29273052</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janssen</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of the allosteric P2X7 receptor antagonist [(11)C]SMW139 as a PET tracer of microglial activation</article-title>
<source/>Sci Rep
          <year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>6580</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-24814-0</pub-id>
<pub-id pub-id-type="pmid">29700413</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Territo</surname>
<given-names>PR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of (11)C-GSK1482160 for targeting the P2X7 receptor as a biomarker for neuroinflammation</article-title>
<source/>J Nucl Med
          <year>2017</year>
<volume>58</volume>
<issue>3</issue>
<fpage>458</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.116.181354</pub-id>
<pub-id pub-id-type="pmid">27765863</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berdyyeva</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PET imaging of the P2X7 ion channel with a novel tracer [(18)F]JNJ-64413739 in a rat model of neuroinflammation</article-title>
<source/>Mol Imaging Biol
          <year>2019</year>
<volume>21</volume>
<fpage>871</fpage>
<lpage>878</lpage>
<pub-id pub-id-type="doi">10.1007/s11307-018-01313-2</pub-id>
<pub-id pub-id-type="pmid">30632003</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolb</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical evaluation and non-human primate receptor occupancy study of (18)F-JNJ-64413739, a novel PET radioligand for P2X7 receptors</article-title>
<source/>J Nucl Med
          <year>2019</year>
<volume>60</volume>
<fpage>1154</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.118.212696</pub-id>
<pub-id pub-id-type="pmid">30733317</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koole</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(18)F-JNJ-64413739, a novel PET ligand for the P2X7 ion channel: radiation dosimetry, kinetic modeling, test-retest variability and occupancy of the P2X7 antagonist JNJ-54175446</article-title>
<source/>J Nucl Med
          <year>2019</year>
<volume>60</volume>
<fpage>683</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.118.216747</pub-id>
<pub-id pub-id-type="pmid">30262518</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villa</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state</article-title>
<source/>Theranostics
          <year>2018</year>
<volume>8</volume>
<issue>19</issue>
<fpage>5400</fpage>
<lpage>5418</lpage>
<pub-id pub-id-type="doi">10.7150/thno.25572</pub-id>
<pub-id pub-id-type="pmid">30555554</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiSabato</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Godbout</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Neuroinflammation: the devil is in the details</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>139</volume>
<issue>Suppl 2</issue>
<fpage>136</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13607</pub-id>
<pub-id pub-id-type="pmid">26990767</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawabori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yenari</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Inflammatory responses in brain ischemia</article-title>
<source/>Curr Med Chem
          <year>2015</year>
<volume>22</volume>
<issue>10</issue>
<fpage>1258</fpage>
<lpage>1277</lpage>
<pub-id pub-id-type="doi">10.2174/0929867322666150209154036</pub-id>
<pub-id pub-id-type="pmid">25666795</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosomi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Watabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammatory projections after focal brain injury trigger neuronal network disruption: an (18)F-DPA714 PET study in mice</article-title>
<source/>Neuroimage Clin
          <year>2018</year>
<volume>20</volume>
<fpage>946</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.1016/j.nicl.2018.09.031</pub-id>
<pub-id pub-id-type="pmid">30312938</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Role of neuroinflammation in neurodegenerative diseases (review)</article-title>
<source/>Mol Med Rep
          <year>2016</year>
<volume>13</volume>
<issue>4</issue>
<fpage>3391</fpage>
<lpage>3396</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2016.4948</pub-id>
<pub-id pub-id-type="pmid">26935478</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prata</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>MI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bridging autism spectrum disorders and schizophrenia through inflammation and biomarkersâpre-clinical and clinical investigations</article-title>
<source/>J Neuroinflammation
          <year>2017</year>
<volume>14</volume>
<issue>1</issue>
<fpage>179</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-017-0938-y</pub-id>
<pub-id pub-id-type="pmid">28870209</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vivash</surname>
<given-names>L</given-names>
</name>
<name>
<surname>OâBrien</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Imaging microglial activation with TSPO PET: lighting up neurologic diseases?</article-title>
<source/>J Nucl Med
          <year>2016</year>
<volume>57</volume>
<issue>2</issue>
<fpage>165</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.114.141713</pub-id>
<pub-id pub-id-type="pmid">26697963</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreisl</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fujimura</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of [<sup>11</sup>C]-(R)-PK 11195 and [<sup>11</sup>C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker</article-title>
<source/>NeuroImage
          <year>2010</year>
<volume>49</volume>
<fpage>2924</fpage>
<lpage>2932</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.11.056</pub-id>
<pub-id pub-id-type="pmid">19948230</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Telu</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title><sup>11</sup>C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than <sup>11</sup>C-( R)-PK11195</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2018</year>
<volume>38</volume>
<fpage>393</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1177/0271678X17699223</pub-id>
<pub-id pub-id-type="pmid">28322082</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doorduin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>James</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kassiou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>EF</given-names>
</name>
</person-group>
<article-title>[<sup>11</sup>C]-DPA-713 and [<sup>18</sup>F]-DPA-714 as new PET tracers for TSPO: a comparison with [<sup>11</sup>C]-(R)-PK11195 in a rat model of herpes encephalitis</article-title>
<source/>Mol Imaging Biol
          <year>2009</year>
<volume>11</volume>
<fpage>386</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1007/s11307-009-0211-6</pub-id>
<pub-id pub-id-type="pmid">19330384</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Yeo</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Gunn</surname>
<given-names>RN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2012</year>
<volume>32</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2011.147</pub-id>
<pub-id pub-id-type="pmid">22008728</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavisse</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guillermier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Herard</surname>
<given-names>AS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>10809</fpage>
<lpage>10818</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1487-12.2012</pub-id>
<pub-id pub-id-type="pmid">22875916</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of recanalization of occluded middle cerebral artery and restored cerebral blood flow in rats with transient brain ischemia: a combination study of digital subtraction angiography and <sup>15</sup>O-water positron emission tomography</article-title>
<source/>Cereb Blood Flow Metabolism
          <year>2015</year>
<volume>26</volume>
<issue>2</issue>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.16977/cbfm.26.2_1</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koizumi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oneda</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Experimental studies of ischemic brain edema. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemia area</article-title>
<source/>Jpn J Stroke
          <year>1986</year>
<volume>8</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.3995/jstroke.8.1</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boisgard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Theze</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2010</year>
<volume>30</volume>
<issue>1</issue>
<fpage>230</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2009.205</pub-id>
<pub-id pub-id-type="pmid">19794397</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boisgard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kassiou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dolle</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tavitian</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Reduced PBR/TSPO expression after minocycline treatment in a rat model of focal cerebral ischemia: a PET study using [(18)F]DPA-714</article-title>
<source/>Mol Imaging Biol
          <year>2011</year>
<volume>13</volume>
<issue>1</issue>
<fpage>10</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1007/s11307-010-0324-y</pub-id>
<pub-id pub-id-type="pmid">20383592</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Itokazu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6 mice</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>7</issue>
<fpage>e41892</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0041892</pub-id>
<pub-id pub-id-type="pmid">22911864</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosomi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Watabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ogura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myeloid-derived suppressor cells infiltrate the brain and suppress neuroinflammation in a mouse model of focal traumatic brain injury</article-title>
<source/>Neuroscience
          <year>2019</year>
<volume>406</volume>
<fpage>457</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2019.03.015</pub-id>
<pub-id pub-id-type="pmid">30880103</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Okauchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<issue>12</issue>
<fpage>4720</fpage>
<lpage>4730</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3076-10.2011</pub-id>
<pub-id pub-id-type="pmid">21430171</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okauchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Inaji</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimerâs and other CNS pathologies</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<issue>47</issue>
<fpage>12255</fpage>
<lpage>12267</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2312-08.2008</pub-id>
<pub-id pub-id-type="pmid">19020019</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maier</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Wehrl</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion</article-title>
<source/>Nat Med
          <year>2014</year>
<volume>20</volume>
<issue>12</issue>
<fpage>1485</fpage>
<lpage>1492</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3734</pub-id>
<pub-id pub-id-type="pmid">25384087</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukuri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takashima-Hirano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tokuda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester</article-title>
<source/>J Nucl Med
          <year>2011</year>
<volume>52</volume>
<issue>7</issue>
<fpage>1094</fpage>
<lpage>1101</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.110.084046</pub-id>
<pub-id pub-id-type="pmid">21680698</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukuri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mawatari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Doi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Detection of cyclooxygenase-1 in activated microglia during amyloid plaque progression: PET studies in Alzheimerâs disease model mice</article-title>
<source/>J Nucl Med
          <year>2016</year>
<volume>57</volume>
<issue>2</issue>
<fpage>291</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.115.166116</pub-id>
<pub-id pub-id-type="pmid">26585055</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Momosaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Omachi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamato</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>[11C]PK11195 PET imaging of spinal glial activation after nerve injury in rats</article-title>
<source/>NeuroImage
          <year>2013</year>
<volume>79</volume>
<fpage>121</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.04.039</pub-id>
<pub-id pub-id-type="pmid">23611861</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belloli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zanotti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Murtaj</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mazzon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Di Grigoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Monterisi</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(18)F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis</article-title>
<source/>J Neuroinflammation
          <year>2018</year>
<volume>15</volume>
<issue>1</issue>
<fpage>33</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-017-1044-x</pub-id>
<pub-id pub-id-type="pmid">29402285</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higuchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo imaging of neuroinflammation in Alzheimerâs disease</article-title>
<source/>Clin Experiment Neuroimmunol
          <year>2016</year>
<volume>7</volume>
<fpage>139</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1111/cen3.12308</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvathenani</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Tertyshnikova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Posmantur</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimerâs disease</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<issue>15</issue>
<fpage>13309</fpage>
<lpage>13317</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M209478200</pub-id>
<pub-id pub-id-type="pmid">12551918</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Ase</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kinsara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Michell-Robinson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>SY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>P2Y12 expression and function in alternatively activated human microglia</article-title>
<source/>Neurol Neuroimmunol Neuroinflamm
          <year>2015</year>
<volume>2</volume>
<issue>2</issue>
<fpage>e80</fpage>
<pub-id pub-id-type="doi">10.1212/NXI.0000000000000080</pub-id>
<pub-id pub-id-type="pmid">25821842</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolb</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Barret</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Constantinescu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical evaluation and non-human primate receptor occupancy study of (18)F-JNJ-64413739, a novel PET radioligand for P2X7 receptors</article-title>
<source/>J Nucl Med
          <year>2019</year>
<volume>60</volume>
<fpage>1154</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.118.212696</pub-id>
<pub-id pub-id-type="pmid">30733317</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koole</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hijzen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ravenstijn</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vandermeulen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Van Weehaeghe</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(18)F-JNJ-64413739, a novel PET ligand for the P2X7 ion channel: radiation dosimetry, kinetic modeling, test-retest variability and occupancy of the P2X7 antagonist JNJ-54175446</article-title>
<source/>J Nucl Med
          <year>2019</year>
<volume>60</volume>
<fpage>683</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.118.216747</pub-id>
<pub-id pub-id-type="pmid">30262518</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Zhequan</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Qingyu</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Bingxin</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Yingying</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Weijia</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Jing</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Yanzhao</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Hak Soo</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Hongcheng</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Dengfeng</given-names>
</name>
</person-group>
<article-title>P2X7 PET Radioligand 18F-PTTP for Differentiation of Lung Tumor from Inflammation</article-title>
<source/>Journal of Nuclear Medicine
          <year>2019</year>
<volume>60</volume>
<issue>7</issue>
<fpage>930</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.118.222547</pub-id>
<pub-id pub-id-type="pmid">30655332</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanaswami</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bernard-Gauthier</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Josephson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cumming</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vasdev</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO</article-title>
<source/>Mol Imaging
          <year>2018</year>
<volume>17</volume>
<fpage>1536012118792317</fpage>
<pub-id pub-id-type="doi">10.1177/1536012118792317.</pub-id>
<pub-id pub-id-type="pmid">30203712</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadopoulos</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Baraldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guilarte</surname>
<given-names>TR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function</article-title>
<source/>Trends Pharmacol Sci
          <year>2006</year>
<volume>27</volume>
<fpage>402</fpage>
<lpage>409</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2006.06.005</pub-id>
<pub-id pub-id-type="pmid">16822554</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Furutsuka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suhara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>[<sup>11</sup>C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain</article-title>
<source/>Nucl Med Biol
          <year>2003</year>
<volume>30</volume>
<fpage>513</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="doi">10.1016/S0969-8051(03)00016-7</pub-id>
<pub-id pub-id-type="pmid">12831989</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suhara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel peripheral benzodiazepine receptor ligand [<sup>11</sup>C]DAA1106 for PET: an imaging tool for glial cells in the brain</article-title>
<source/>Synapse
          <year>2004</year>
<volume>52</volume>
<fpage>283</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1002/syn.20027</pub-id>
<pub-id pub-id-type="pmid">15103694</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikoma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yasuno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [<sup>11</sup>C]DAA1106</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2007</year>
<volume>27</volume>
<fpage>173</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600325</pub-id>
<pub-id pub-id-type="pmid">16685259</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Furutsuka</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>[<sup>18</sup>F]FMDAA1106 and [<sup>18</sup>F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR)</article-title>
<source/>Bioorg Med Chem Lett
          <year>2003</year>
<volume>13</volume>
<fpage>201</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/S0960-894X(02)00886-7</pub-id>
<pub-id pub-id-type="pmid">12482423</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[<sup>18</sup>F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain</article-title>
<source/>J Med Chem
          <year>2004</year>
<volume>47</volume>
<fpage>2228</fpage>
<lpage>2235</lpage>
<pub-id pub-id-type="doi">10.1021/jm0304919</pub-id>
<pub-id pub-id-type="pmid">15084121</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ikoma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yasuno</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantitative analyses of <sup>18</sup>F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain</article-title>
<source/>J Nucl Med
          <year>2006</year>
<volume>47</volume>
<fpage>43</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">16391186</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kumata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title><sup>11</sup>C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain</article-title>
<source/>J Nucl Med
          <year>2007</year>
<volume>48</volume>
<fpage>1853</fpage>
<lpage>1861</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.107.043505</pub-id>
<pub-id pub-id-type="pmid">17978354</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyoshi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arakawa</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantitative analysis of peripheral benzodiazepine receptor in the human brain using PET with <sup>11</sup>C-AC-5216</article-title>
<source/>J Nucl Med
          <year>2009</year>
<volume>50</volume>
<fpage>1095</fpage>
<lpage>1101</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.109.062554</pub-id>
<pub-id pub-id-type="pmid">19525461</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kumata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>[<sup>18</sup>F]FEAC and [<sup>18</sup>F]FEDAC: two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain</article-title>
<source/>Bioorg Med Chem Lett
          <year>2009</year>
<volume>19</volume>
<fpage>1707</fpage>
<lpage>1710</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmcl.2009.01.093</pub-id>
<pub-id pub-id-type="pmid">19217778</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kumata</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title><sup>18</sup>F-FEAC and <sup>18</sup>F-FEDAC: PET of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain</article-title>
<source/>J Nucl Med
          <year>2010</year>
<volume>51</volume>
<fpage>1301</fpage>
<lpage>1309</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.109.072223</pub-id>
<pub-id pub-id-type="pmid">20660373</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kumata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takei</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficient radiosynthesis and non-clinical safety tests of the TSPO radioprobe [<sup>18</sup>F]FEDAC: prerequisites for clinical application</article-title>
<source/>Nucl Med Biol
          <year>2016</year>
<volume>43</volume>
<fpage>445</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1016/j.nucmedbio.2016.04.004</pub-id>
<pub-id pub-id-type="pmid">27183465</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kumata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujinaga</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo imaging and quantitative analysis of TSPO in rat peripheral tissues using small-animal PET with [<sup>18</sup>F]FEDAC</article-title>
<source/>Nucl Med Biol
          <year>2010</year>
<volume>37</volume>
<fpage>853</fpage>
<lpage>860</lpage>
<pub-id pub-id-type="doi">10.1016/j.nucmedbio.2010.04.183</pub-id>
<pub-id pub-id-type="pmid">20870161</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatori</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PET imaging of lung inflammation with [<sup>18</sup>F]FEDAC, a radioligand for translocator protein (18 kDa)</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e45065</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0045065</pub-id>
<pub-id pub-id-type="pmid">22984611</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hatori</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease</article-title>
<source/>J Hepatol
          <year>2012</year>
<volume>57</volume>
<fpage>1076</fpage>
<lpage>1082</lpage>
<pub-id pub-id-type="doi">10.1016/j.jhep.2012.07.002</pub-id>
<pub-id pub-id-type="pmid">22796156</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatori</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Visualization of acute liver damage induced by cycloheximide in rats using PET with [<sup>18</sup>F]FEDAC, a radiotracer for translocator protein (18 kDa)</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e86625</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0086625</pub-id>
<pub-id pub-id-type="pmid">24466178</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatori</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Utility of translocator protein (18 kDa) as a molecular imaging biomarker to monitor the progression of liver fibrosis</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>17327</fpage>
<pub-id pub-id-type="doi">10.1038/srep17327</pub-id>
<pub-id pub-id-type="pmid">26612465</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ichimaru</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>[<sup>11</sup>C]DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model</article-title>
<source/>J Neuroimmune Pharmacol
          <year>2012</year>
<volume>7</volume>
<fpage>231</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-011-9322-3</pub-id>
<pub-id pub-id-type="pmid">22038158</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title><sup>18</sup>F-FEDAC as a targeting agent for activated macrophages in DBA/1 mice with collagen-induced arthritis: comparison with <sup>18</sup>F-FDG</article-title>
<source/>J Nucl Med
          <year>2018</year>
<volume>59</volume>
<fpage>839</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.117.200667</pub-id>
<pub-id pub-id-type="pmid">29326355</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>EJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo imaging of activated macrophages by <sup>18</sup>F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs)</article-title>
<source/>Biochem Biophys Res Commun
          <year>2018</year>
<volume>506</volume>
<fpage>216</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2018.10.083</pub-id>
<pub-id pub-id-type="pmid">30343885</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Microglia and neurodegeneration: the role of systemic inflammation</article-title>
<source/>Glia
          <year>2013</year>
<volume>61</volume>
<fpage>71</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22350</pub-id>
<pub-id pub-id-type="pmid">22674585</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezaie</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Male</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Microglia in the human fetal spinal cord; patterns of distribution, morphology and phenotype</article-title>
<source/>Dev Brain Res
          <year>1999</year>
<volume>115</volume>
<fpage>71</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-3806(99)00043-7</pub-id>
<pub-id pub-id-type="pmid">10366704</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lubrich</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Biber</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gebicke-Haerter</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<source/>Mol Brain Res
          <year>1999</year>
<volume>65</volume>
<fpage>198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1016/S0169-328X(99)00016-9</pub-id>
<pub-id pub-id-type="pmid">10064890</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takayanagi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Production of interleukin-12 and expression of its receptors by murine microglia</article-title>
<source/>Brain Res
          <year>1998</year>
<volume>787</volume>
<fpage>139</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(97)01166-9</pub-id>
<pub-id pub-id-type="pmid">9518583</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niimi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kawamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Morimoto-Ishizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takemori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamatodani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Histamine production by cultured microglial cells of the mouse</article-title>
<source/>Neurosci Lett
          <year>2001</year>
<volume>305</volume>
<fpage>181</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(01)01835-3</pub-id>
<pub-id pub-id-type="pmid">11403935</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Irie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Urae</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Urae</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Akazawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Pepstatin a induces extracellular acidification distinct from aspartic protease inhibition in microglial cell lines</article-title>
<source/>Glia
          <year>2003</year>
<volume>43</volume>
<fpage>167</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1002/glia.10237</pub-id>
<pub-id pub-id-type="pmid">12838508</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kajizono</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Interleukin-4-induced selective clearance of oligomeric beta-amyloid peptide1-42 by rat primary type-2 microglia</article-title>
<source/>J Immunol
          <year>2008</year>
<volume>181</volume>
<fpage>6503</fpage>
<lpage>6513</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.181.9.6503</pub-id>
<pub-id pub-id-type="pmid">18941241</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ling</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>WC</given-names>
</name>
</person-group>
<article-title>The origin and nature of ramified and amoeboid microglia: a historical review and current concepts</article-title>
<source/>Glia
          <year>1993</year>
<volume>7</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1002/glia.440070105</pub-id>
<pub-id pub-id-type="pmid">8423067</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Marunouchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Activation and proliferation of the isolated microglia by colony stimulating factor-1 and possible involvement of protein kinase C</article-title>
<source/>Brain Res
          <year>1990</year>
<volume>509</volume>
<fpage>119</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(90)90317-5</pub-id>
<pub-id pub-id-type="pmid">2306629</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witmer-Pack</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Schuler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McWilliam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Inaba</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Steinman</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Identification of macrophages and dendritic cells in the osteopetrotic (<italic>op/op</italic>) mouse</article-title>
<source/>J Cell Sci
          <year>1993</year>
<volume>104</volume>
<fpage>1021</fpage>
<lpage>1029</lpage>
<pub-id pub-id-type="pmid">8314887</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiktor</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Bartocci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Sell</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>ER</given-names>
</name>
</person-group>
<article-title>Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (<italic>op/op</italic>) mouse</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1990</year>
<volume>87</volume>
<fpage>4828</fpage>
<lpage>4832</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.87.12.4828</pub-id>
<pub-id pub-id-type="pmid">2191302</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kunisada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sudo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shultz</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene</article-title>
<source/>Nature
          <year>1990</year>
<volume>345</volume>
<fpage>442</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.1038/345442a0</pub-id>
<pub-id pub-id-type="pmid">2188141</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gehrmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kreutzberg</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Microglia: intrinsic immuneffector cell of the brain</article-title>
<source/>Brain Res Brain Res Rev
          <year>1995</year>
<volume>20</volume>
<fpage>269</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/0165-0173(94)00015-H</pub-id>
<pub-id pub-id-type="pmid">7550361</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler-Heitbrock</surname>
<given-names>HWL</given-names>
</name>
<name>
<surname>Ulevitch</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>CD14: cell surface receptor and differentiation marker</article-title>
<source/>Immunol Today
          <year>1993</year>
<volume>14</volume>
<fpage>121</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/0167-5699(93)90212-4</pub-id>
<pub-id pub-id-type="pmid">7682078</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>Macrophage scavenger receptors</article-title>
<source/>Curr Opin Lipidol
          <year>1994</year>
<volume>5</volume>
<fpage>143</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1097/00041433-199404000-00011</pub-id>
<pub-id pub-id-type="pmid">8044417</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marunouchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Morphological transformation of microglia in vitro</article-title>
<source/>Brain Res
          <year>1991</year>
<volume>545</volume>
<fpage>301</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(91)91302-H</pub-id>
<pub-id pub-id-type="pmid">1907214</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Marunouchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Production of interleukin-5 by mouse astrocytes and microglia in culture</article-title>
<source/>Neurosci Lett
          <year>1993</year>
<volume>155</volume>
<fpage>175</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3940(93)90701-L</pub-id>
<pub-id pub-id-type="pmid">8377948</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marunouchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Induction of functional interleukin-2 receptor in mouse microglia</article-title>
<source/>J Neurochem
          <year>1995</year>
<volume>64</volume>
<fpage>1973</fpage>
<lpage>1979</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1995.64051973.x</pub-id>
<pub-id pub-id-type="pmid">7536800</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacs</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brock</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Varesio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>IL-2 induction of IL-1 beta mRNA expression in monocytes</article-title>
<source/>J Immunol
          <year>1989</year>
<volume>143</volume>
<fpage>3532</fpage>
<lpage>3537</lpage>
<pub-id pub-id-type="pmid">2584705</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McCartney-Francis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wahl</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Katona</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Monocyte interleukin-2-receptor gene expression and interleukin-2 augmentation of microbicidal activity</article-title>
<source/>J Immunol
          <year>1987</year>
<volume>139</volume>
<fpage>1342</fpage>
<lpage>1347</lpage>
<pub-id pub-id-type="pmid">3039002</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marunouchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide</article-title>
<source/>Biochem Biophys Res Commun
          <year>1992</year>
<volume>189</volume>
<fpage>869</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1016/0006-291X(92)92284-5</pub-id>
<pub-id pub-id-type="pmid">1282000</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lassmann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schmied</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vass</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hickey</surname>
<given-names>WF</given-names>
</name>
</person-group>
<article-title>Bone marrow derived elements and resident microglia in brain inflammation</article-title>
<source/>Glia
          <year>1993</year>
<volume>7</volume>
<fpage>19</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1002/glia.440070106</pub-id>
<pub-id pub-id-type="pmid">7678581</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Absence of donor-type major histocompatibility complex class I antigen- bearing microglia in the rat central nervous system of radiation bone marrow chimeras</article-title>
<source/>J Neuroimmunol
          <year>1987</year>
<volume>17</volume>
<fpage>71</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/0165-5728(87)90032-4</pub-id>
<pub-id pub-id-type="pmid">3316271</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Immunohistochemical analysis of the rat central nervous system during experimental allergic encephalomyelitis, with special reference to Ia-positive cells with dendritic morphology</article-title>
<source/>J Immunol
          <year>1986</year>
<volume>136</volume>
<fpage>3668</fpage>
<lpage>3676</lpage>
<pub-id pub-id-type="pmid">3084638</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocha</surname>
<given-names>B</given-names>
</name>
<name>
<surname>von</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Guy</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Selection of intraepithelial lymphocytes with CD8 alpha/alpha co-receptors by self-antigen in the murine gut</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1992</year>
<volume>89</volume>
<fpage>5336</fpage>
<lpage>5340</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.89.12.5336</pub-id>
<pub-id pub-id-type="pmid">1608941</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Akagawa</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Fukayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kadokura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tokunaga</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro</article-title>
<source/>J Immunol
          <year>1991</year>
<volume>147</volume>
<fpage>1266</fpage>
<lpage>1272</lpage>
<pub-id pub-id-type="pmid">1869822</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dexter</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Nanayakkara</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Goss-Sampson</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>CD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nigral dopaminergic cell loss in vitamin E deficient rats</article-title>
<source/>Neuroreport
          <year>1994</year>
<volume>5</volume>
<fpage>1773</fpage>
<lpage>1776</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-199409080-00022</pub-id>
<pub-id pub-id-type="pmid">7827329</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagatsu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cellular and molecular mechanisms of Parkinsonâs disease: neurotoxins, causative genes, and inflammatory cytokines</article-title>
<source/>Cell Mol Neurobiol
          <year>2006</year>
<volume>26</volume>
<fpage>781</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.1007/s10571-006-9061-9</pub-id>
<pub-id pub-id-type="pmid">16823625</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<mixed-citation publication-type="other">Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinsonâs disease. J Neural Transm Suppl. 2006;70:373â81.</mixed-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hishikawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nagatsu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hashizume</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Distribution of major histocompatibility complex class Il-positive microglia and cytokine profile of Parkinsonâs disease brains</article-title>
<source/>Acta Neuropathol
          <year>2003</year>
<volume>106</volume>
<fpage>518</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-003-0766-2</pub-id>
<pub-id pub-id-type="pmid">14513261</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Jackson-Lewis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tieu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Teismann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vadseth</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blockade of microglial activation is neuroprotective in the 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<fpage>1763</fpage>
<lpage>1771</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-05-01763.2002</pub-id>
<pub-id pub-id-type="pmid">11880505</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Teismann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tieu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jackson-Lewis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ischiropoulos</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NADPH oxidase mediates oxidative stress in the 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson disease</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2003</year>
<volume>100</volume>
<fpage>6145</fpage>
<lpage>6150</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0937239100</pub-id>
<pub-id pub-id-type="pmid">12721370</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haneda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Isobe</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via PI3K/Akt and/or ERK pathway</article-title>
<source/>Neurosci Res
          <year>2006</year>
<volume>56</volume>
<fpage>294</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1016/j.neures.2006.07.009</pub-id>
<pub-id pub-id-type="pmid">16978723</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hashida</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muramatsu</surname>
<given-names>SI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl 1,2,3,6-tetra-hydropyridine</article-title>
<source/>J Neurosci Res
          <year>2007</year>
<volume>85</volume>
<fpage>1752</fpage>
<lpage>1761</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.21241</pub-id>
<pub-id pub-id-type="pmid">17469135</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ninomiya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effect of exogenous microglia in global brain ischemia</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2007</year>
<volume>27</volume>
<fpage>488</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600362</pub-id>
<pub-id pub-id-type="pmid">16820801</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilhardt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Plastre</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wiznerowicz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kiyokawa</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The HIV-1 Nef protein and phagocyte NADPH oxidase activation</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>42136</fpage>
<lpage>42143</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M200862200</pub-id>
<pub-id pub-id-type="pmid">12207012</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marunouchi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Cytokine network in the central nervous system and its roles in growth and differentiation of glial and neuronal cells</article-title>
<source/>Int J Dev Neurosci
          <year>1995</year>
<volume>13</volume>
<fpage>253</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="doi">10.1016/0736-5748(94)00076-F</pub-id>
<pub-id pub-id-type="pmid">7572279</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alderman</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Frothingham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sempowski</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Validation of an animal isolation imaging chamber for use in animal biosafety level-3 containment</article-title>
<source/>Appl Biosaf
          <year>2010</year>
<volume>15</volume>
<fpage>62</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1177/153567601001500203</pub-id>
<pub-id pub-id-type="pmid">23226978</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>XJ</given-names>
</name>
</person-group>
<article-title>Severe fever with thrombocytopenia syndrome and its pathogen SFTSV</article-title>
<source/>Microbes Infect
          <year>2015</year>
<volume>17</volume>
<fpage>149</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/j.micinf.2014.12.002</pub-id>
<pub-id pub-id-type="pmid">25498868</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayasaka</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fuchigami</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>18F-FDG PET imaging for identifying the dynamics of intestinal disease caused by SFTSV infection in a mouse model</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>140</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.6645</pub-id>
<pub-id pub-id-type="pmid">26700962</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchigami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oyadomari</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of a (68)Ge/(68)Ga generator system using polysaccharide polymers and its application in PET imaging of tropical infectious diseases. <italic>ACS</italic></article-title>
<source/>Omega
          <year>2017</year>
<volume>2</volume>
<fpage>1400</fpage>
<lpage>1407</lpage>
<pub-id pub-id-type="doi">10.1021/acsomega.7b00147</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sauerbrunn</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Hubner</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Ga-67 citrate imaging in tumors of the genito-urinary tract: report of cooperative study</article-title>
<source/>J Nucl Med
          <year>1978</year>
<volume>19</volume>
<fpage>470</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">205635</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossleigh</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Mackey</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Bargwanna</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Nayanar</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>Pediatric solid tumors: evaluation by gallium-67 SPECT studies</article-title>
<source/>J Nucl Med
          <year>1990</year>
<volume>31</volume>
<fpage>168</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">2179485</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsan</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Mechanism of gallium-67 accumulation in inflammatory lesions</article-title>
<source/>J Nucl Med
          <year>1985</year>
<volume>26</volume>
<fpage>88</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">3880816</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mougneau</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bihl</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Glaichenhaus</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Cell biology and immunology of Leishmania</article-title>
<source/>Immunol Rev
          <year>2011</year>
<volume>240</volume>
<fpage>286</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00983.x</pub-id>
<pub-id pub-id-type="pmid">21349100</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<sub-article article-type="research-article" id="Sec1">
<front-stub>
<title-group>
<article-title>Mechanisms of FDG Accumulation in Inflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kubota</surname>
<given-names>Kazuo</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar1">
<title>Abstract</title>
<p id="Par2">
FDG-PET/CT has recently emerged as a useful tool for the evaluation of inflammatory diseases too, in addition to that of malignant diseases. The imaging is based on active glucose utilization by inflammatory tissue. Autoradiography studies have demonstrated high FDG uptake in macrophages, granulocytes, fibroblasts, and granulation tissue. Especially, activated macrophages are responsible for the elevated FDG uptake in some types of inflammation. According to one study, after activation by lipopolysaccharide of cultured macrophages, the [<sup>14</sup>C]2DG uptake by the cells doubled, reaching the level seen in glioblastoma cells. In activated macrophages, increase in the expression of total GLUT1 and redistributions from the intracellular compartments toward the cell surface have been reported. In one rheumatoid arthritis model, following stimulation by hypoxia or TNF-Î±, the highest elevation of the [<sup>3</sup>H]FDG uptake was observed in the fibroblasts, followed by that in macrophages and neutrophils. As the fundamental mechanism of elevated glucose uptake in both cancer cells and inflammatory cells, activation of glucose metabolism as an adaptive response to a hypoxic environment has been reported, with transcription factor HIF-1Î± playing a key role. Inflammatory cells and cancer cells seem to share the same molecular mechanism of elevated glucose metabolism, lending support to the notion of usefulness of FDGPET/CT for the evaluation of inflammatory diseases, besides cancer.</p>
<p id="Par3"><bold>Keywords</bold>:âMacrophage, Neutrophil, Fibroblast, Granulation tissue, GLUT, HIF-1Î±, FDG</p>
</sec>
<sec id="Sec2">
<title>Introduction</title>
<p id="Par4">Fluorine-18-labeled 2-deoxy-2-fluoro-glucose (FDG) is used as a radiopharmaceutical in PET for evaluating glucose metabolism, and accumulates in malignant tissues because of the enhanced glucose utilization by neoplastic cells. Because of the increased metabolic demand for glucose, elevated activity of hexokinase and elevated expression of glucose transporter have been shown in tumor tissues [<xref ref-type="bibr" rid="CR1">1</xref>]. Various applications of FDG-PET have been extensively studied in the field of clinical oncology, and the imaging modality, now used worldwide, is recognized as a powerful diagnostic modality for cancer [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. In 1989, elevated FDG uptake was reported in two patients with abdominal abscesses [<xref ref-type="bibr" rid="CR4">4</xref>]. This was followed by reports of FDG uptake in brain abscess [<xref ref-type="bibr" rid="CR5">5</xref>], tuberculosis, aspergillosis, sarcoidosis, and so on. In addition, early postoperative scarring and early inflammatory reactions after radiotherapy were also reported to show increased FDG uptake. Thus, elevation in glucose metabolism is not only specific for cancer but also seen in inflammation. Because FDG uptake is seen in benign inflammatory diseases as well, the accuracy of FDG-PET for the diagnosis of cancer is not 100% [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
</sec>
<sec id="Sec3">
<title>FDG Uptake by Inflammatory Tissues and Cells</title>
<p id="Par5">Although the metabolic fate of FDG
is well known, its cellular distribution within tumors or sites of inflammation has not yet been described. To clarify the mechanisms of FDG uptake by inflammatory and tumor tissues, we performed autoradiographic studies. To demonstrate the cellular localization of FDG and [<sup>3</sup>H]2DG uptake by tumors in vivo, C3H/He mice with subcutaneously transplanted FM3A tumors were studied 1Â h after intravenous injection of FDG or [<sup>3</sup>H]2DG. Newly formed granulation tissue around tumors and macrophages, which had massively infiltrated the marginal areas surrounding the necrotic areas of the tumor, showed a higher FDG uptake than the viable tumor cells. A maximum of 24% of the glucose utilization was derived from the non-neoplastic tissues in these tumors (Fig. <xref ref-type="fig" rid="Fig1">1.1</xref>). The strong accumulation of FDG in these tumors was thought to represent both the high metabolic activity of the viable tumor cells and that of the tumor-associated inflammatory cells, especially activated macrophages. These results indicate that not only glucose uptake by the tumor cells but also that by non-neoplastic cellular elements which appear in association with the growth or necrosis of tumor cells should be considered for a precise analysis of FDG uptake in tumors, especially after radiotherapy (Fig. <xref ref-type="fig" rid="Fig2">1.2</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].<fig id="Fig1"><label>Fig. 1.1</label><caption><p>A combination of double-tracer macro-autoradiograms and microscopy. Images of 18F-FDG distribution (<bold>a</bold>) and 3HThd (<bold>b</bold>), a photomicrograph of the tissue specimen (<bold>c</bold>) and an illustration of the micrograph (<bold>d</bold>). <italic>T</italic> tumor calls, <italic>G</italic> granulation tissue, <italic>N</italic> necrosis, <italic>H</italic> host normal tissue. Scale bar: 2 mm. Newly formed granulation tissue around the tumor and macrophages infiltrating the periphery of the necrotic areas of the tumor showed higher uptakes of FDG than the viable tumor cells. (From Ref. [<xref ref-type="bibr" rid="CR7">7</xref>])</p></caption><graphic id="MO1" xlink:href="477582_1_En_1_Fig1_HTML"></graphic></fig>
<fig id="Fig2"><label>Fig. 1.2</label><caption><p>A model of FDG accumulation in various cellular elements in a tumor. (Modified from Ref. [<xref ref-type="bibr" rid="CR8">8</xref>])</p></caption><graphic id="MO2" xlink:href="477582_1_En_1_Fig2_HTML"></graphic></fig>
</p>
<p id="Par6">FDG uptake by inflammatory tissues was investigated by Yamada et al. [<xref ref-type="bibr" rid="CR9">9</xref>]. A rat model of chemically induced inflammation using turpentine oil was used. A time-course study of the FDG tissue distribution showed that the uptake of FDG
in inflammatory tissue increased gradually until 60Â min, followed by a steady decrease thereafter. A longitudinal study showed that the uptake increased progressively after the start of inflammation, peaking at 4Â days after the inoculation, and then gradually decreased (Fig. <xref ref-type="fig" rid="Fig3">1.3</xref>). These findings suggested that FDG uptake may reach a maximum during the subacute phase of inflammation, and then slightly decreases during the chronic phase of inflammation. An autoradiography study showed a high FDG uptake in the abscess wall, consisting of an inflammatory cell layer and granulation tissue. At the cellular level, the highest radioactivity was found in the marginal zone that contained young fibroblasts, endothelial cells of vessels, and phagocytes consisting of neutrophils and macrophages, followed by that in the neutrophil layer and the granulation tissue layer (Fig. <xref ref-type="fig" rid="Fig4">1.4</xref>). FDG uptake by inflammatory tissue seems to represent the activity of immune cells and fibroblasts mobilized to the lesion.<fig id="Fig3"><label>Fig. 1.3</label><caption><p>FDG uptake changes along with the age of inflammation. FDG uptake by inflammatory tissue, muscle, and blood are plotted against the days after inoculation of turpentine oil. The highest uptake by inflammatory tissue was observed on day 4, which represented the subacute phase histologically (<italic>n</italic>Â =Â 5, each point). (From Ref. [<xref ref-type="bibr" rid="CR9">9</xref>])</p></caption><graphic id="MO3" xlink:href="477582_1_En_1_Fig3_HTML"></graphic></fig>
<fig id="Fig4"><label>Fig. 1.4</label><caption><p>
Macro-autoradiogram (<bold>a</bold>) and the corresponding section (<bold>b</bold>) of inflammatory tissue 4Â days after inoculation of turpentine oil. The center (C), surrounded by inflammatory cells (IC), thick granulation tissue (GT), and edematous subcutaneous tissue (ST). Scale bar 0.4 mm. (From Ref. [<xref ref-type="bibr" rid="CR9">9</xref>])</p></caption><graphic id="MO4" xlink:href="477582_1_En_1_Fig4_HTML"></graphic></fig>
</p>
<p id="Par7">Mochizuki et al. [<xref ref-type="bibr" rid="CR10">10</xref>] compared the FDG
uptake by experimental hepatoma and by tissue with experimental infection with <italic>Staphylococcus aureus</italic>. The expressions of GLUT1 and GLUT3 were also studied in both the tumor and infected tissue by immunostaining. Uptake by the tumor tissue was significantly higher than that by the infected tissue. Both the tumor and infected tissue showed strong expression of GLUT1 and GLUT 3, although the expression level of GLUT1 was significantly higher in the tumor than in the infected tissue. GLUT1 may be responsible for FDG uptake in both tumor tissue and infected tissue.</p>
<p id="Par8">Zhao et al. [<xref ref-type="bibr" rid="CR11">11</xref>] compared the two models of inflammation: BCG-induced granuloma simulating sarcoidosis and turpentine oil-induced inflammation. FDG uptake by the granuloma was significantly higher than that by the tissue with chemical-induced inflammation. Their results explained the very high FDG uptake in sarcoidosis, equivalent to the uptake in cancer. However, the main objective of their study was not to compare the models of inflammation, but to compare the uptakes
of <sup>14</sup>C-methionine, <sup>18</sup>F-fluorothymidine, and FDG. <sup>14</sup>C-methionine showed the best results for discrimination between tumor and inflammation.</p>
</sec>
<sec id="Sec4">
<title>Activated Macrophages and GLUT</title>
<p id="Par9">Deichen et al. [<xref ref-type="bibr" rid="CR12">12</xref>] studied the uptake
of FDG in isolated human monocyte-macrophages (HMMs) in vitro. FDG uptake by the HMMs increased significantly with the duration of culture, the percent ID/100Â Î¼g being 7.5%Â Â±Â 0.9% (% ID/100Â Î¼g) on day 14. Stimulation by lipopolysaccharide further enhanced the FDG uptake in the HMMs by a factor of 2. Radio-thin layer chromatography of intracellular metabolites revealed that the FDG was trapped by the HMMs mainly as FDG-6-phosphate and FDG-1,6-diphosphate. FDG uptake by the HMMs was almost equal to that by human glioblastoma and pancreatic carcinoma cells.</p>
<p id="Par10">Malide et al. [<xref ref-type="bibr" rid="CR13">13</xref>] reported the changes in the subcellular localization of the glucose transporter proteins GLUT-1, GLUT-3, and GLUT-5 as the human monocytes differentiated into macrophages in culture, and the effects of the activating agents <italic>N</italic>-formyl-methionyl-leucylphenylalanine (fMLP) and phorbol myristate acetate (PMA). Western blot analysis demonstrated progressively increasing GLUT-1 expression, rapidly decreasing GLUT-3 expression, and a delayed increase of the GLUT-5 expression during the differentiation process. Confocal microscopy revealed that each isoform exhibited a unique subcellular distribution and cell-activation response. GLUT-1 was localized primarily at the cell surface, but was also detected in the perinuclear region, in a pattern characteristic of recycling endosomes. Activation with fMLP induced similar GLUT-1 and GLUT-5 redistributions from the intracellular compartments toward the cell surface. Addition of PMA elicited a similar translocation of GLUT-1, but GLUT-5 was redistributed from the plasma membrane to a distinct intracellular compartment that appeared connected to the cell surface. These results suggest specific subcellular targeting of each transporter isoform and differential regulation of their trafficking pathways
in cultured macrophages.</p>
</sec>
<sec id="Sec5">
<title>Activated Neutrophils</title>
<p id="Par11">Not only macrophages but also neutrophil granulocytes play a key role in the pathogenesis of various types of inflammation. Jones et al. [<xref ref-type="bibr" rid="CR14">14</xref>] studied [<sup>3</sup>H]DG uptake in neutrophils isolated from human peripheral blood. They found elevated uptake of [<sup>3</sup>H]DG by neutrophils, both after priming with tumor necrotic factor-alpha (TNF-Î±) and after activation with fMLP. It was not correlated with the respiratory burst or secretory activity, but may reflect the polarization and migrational status of these cells. Their study suggested that as far as neutrophils are concerned, priming is the cellular event predominantly responsible for the FDG uptake. Ishimori et al. [<xref ref-type="bibr" rid="CR15">15</xref>] studied immunocompetent BALB/c mice and nude mice administered an intravenous injection of 10Â mg/kg of concanavalin A (Con A). After the injection, the Con A-activated lymphocytes actively took up FDG both in vitro and in vivo, and FDG specifically accumulated in the tissues showing Con A-mediated acute inflammation in the immunocompetent mice.</p>
</sec>
<sec id="Sec6">
<title>Activated Fibroblasts</title>
<p id="Par12">
Rheumatoid arthritis (RA)
is an autoimmune disorder of unknown etiology and is characterized by systematic, symmetric, and erosive synovitis. RA synovitis is characterized by massive leukocyte infiltration, proliferative synovial membranes, and neovascularization, which give rise to a synovial proliferative fibrovascular tissue known as a pannus. Formation of pannus is directly responsible for the cartilage and bone destruction [<xref ref-type="bibr" rid="CR16">16</xref>]. Matsui et al. [<xref ref-type="bibr" rid="CR17">17</xref>] reported the mechanism of FDG accumulation in RA in vivo using a murine collagen-induced arthritis model, as well as [<sup>3</sup>H]FDG uptake in vitro using various cell types. They showed that FDG accumulation increased with the progression of joint swelling. FDG uptake began in the area of inflammatory cell infiltration and synovial cell hyperplasia, and the areas showing strong FDG uptake often coincided with the areas where mixed cellular patterns of macrophages and fibroblasts as well as bone destruction by mature osteoclasts were visible. These findings indicated that FDG accumulation reflected the characteristic changes of pathological progression, such as pannus formation and bone destruction. Based on the findings of in vitro experiments, Matsui et al. suggested that the cell types responsible for FDG uptake were mostly proliferating fibroblasts, with lesser contributions from activated macrophages. FDG uptake by fibroblasts was enhanced in the presence of cytokine stimulation and hypoxia within a joint. Hypoxia is a known feature of the microenvironment in inflamed joints [<xref ref-type="bibr" rid="CR18">18</xref>]. Recently, Garcia-Carbonell et al. directly compared fibroblast-like synoviocytes (FLS) from RA patients and osteoarthritis patients [<xref ref-type="bibr" rid="CR19">19</xref>]. In vitro experiments have shown that the FLS from RA patients were dependent on glycolysis rather than on oxidative phosphorylation, and this difference was more pronounced than that for the FLS from osteoarthritis patients. The expression of GLUT-1 messenger RNA was correlated with the functions of the FLS from the RA patients. These studies showed the importance of fibroblasts in the inflammation in RA.</p>
</sec>
<sec id="Sec7">
<title>Contribution of HIF-1Î±</title>
<p id="Par13">Recently, the processes, at the molecular level, occurring in association with hypoxia and glucose metabolism within tumor and inflammatory tissues have been described. Cramer et al. reported that activation of hypoxia-inducible factor one-alpha (HIF-1Î±) is essential for myeloid cell infiltration and activation in vivo [<xref ref-type="bibr" rid="CR20">20</xref>]. They showed that HIF-1Î± is essential for regulation of the glycolytic capacity of myeloid cells; when HIF-1Î± is knocked out, the cellular ATP pool decreases drastically. This metabolic defect results in a profound impairment of myeloid cell aggregation, motility, invasiveness, and bacterial killing at sites of inflammation where the tissue environment is hypoxic. Thus, HIF-1Î± has a direct regulatory effect on both the survival and functioning of cells in inflammatory microenvironments. Furthermore, the enhanced glycolysis in activated macrophages results in elevation of the FDG uptake. Regarding the molecular mechanisms responsible for the regulation of glycolysis, HIF-1Î± affects both glucose transporter and hexokinase expressions in tumors and inflamed tissues.</p>
<p id="Par14">The significance of hypoxia in tumor pathophysiology has also been described by Denko [<xref ref-type="bibr" rid="CR21">21</xref>]. Usually, proliferation of cancer cells is faster than the growth of capillaries, resulting in inadequate perfusion and hypoxia within the tumor. Activation of HIF-1Î± in the hypoxic tumor shifts the energy metabolism from oxidative phosphorylation to anaerobic glycolysis, saves oxygen, and avoids massive cell death. As a result of the elevated glucose metabolism, FDG-PET serves as a useful imaging modality for cancer patients.</p>
</sec>
<sec id="Sec8">
<title>Conclusion</title>
<p id="Par15">Dominant inflammatory cells activated and responsible for FDG uptake in inflammatory diseases may differ depending upon the disease. All inflammatory cells and cancer cells seem to share the same molecular mechanism of elevated glucose metabolism, lending support to the idea of the usefulness of FDGPET/CT also for the evaluation of inflammatory diseases, besides cancer. Although a guideline [<xref ref-type="bibr" rid="CR22">22</xref>] has been proposed, use of FDGPET/CT for inflammatory diseases is still limited. I hope that this book will help spread knowledge about the application of FDGPET/CT for inflammatory diseases to improve patient management, representing an advance in the field of medicine.</p>
<sec id="FPar2">
<title>Acknowledgement</title>
<p id="Par16">I would like to thank Roko Kubota, PhD, and Susumu Yamada, MD, PhD, for their comments and contribution to our research works that reviewed here.</p>
</sec>
</sec>
</body>
</sub-article>
<sub-article article-type="research-article" id="Sec9">
<front-stub>
<title-group>
<article-title>FDG PET Imaging of Inflammation in Atherosclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ogawa</surname>
<given-names>Mikako</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar3">
<title>Abstract</title>
<p id="Par17">A vulnerable plaque is characterized by a large lipid-rich atheromatous core, a thin fibrous cap, and infiltration by inflammatory cells (e.g., macrophages). The rupture of high-risk, vulnerable plaques can cause thrombosis, the main cause of acute myocardial infarction and stroke. Thus, the detection of vulnerable plaques is clinically important for risk stratification and early administration of treatment. Macrophages play a central role in the destabilization of atherosclerotic lesions. Macrophages are metabolically active; therefore, these plaques can be detected by FDG-PET. Thus far, numerous clinical and basic research studies have been performed to investigate the effectiveness of FDG-PET for the imaging of vulnerable plaques. In addition, it was revealed that the foam cell formation of macrophages affects the accumulation of FDG. Notably, FDG accumulates in pro-atherogenic M1 macrophages rather than anti-inflammatory M2 macrophages. Therefore, assessing the effect of drugs in individual patients is important to monitor the therapeutic effect. Moreover, numerous studies have shown that FDG-PET is useful in evaluating the therapeutic effect of drugs.</p>
<p id="Par18"><bold>Keywords</bold>:âMacrophage, Atherosclerosis, Vulnerable plaque, FDG-PET</p>
</sec>
<sec id="Sec10">
<title>Introduction</title>
<p id="Par19">
Atherosclerotic plaques are classified into two types: stable and vulnerable. Vulnerable plaques are easy to rupture and may cause stroke and heart attack. Therefore, the prompt detection and treatment of vulnerable plaques, prior to the manifestation of symptoms, is of crucial importance. Vulnerable plaques are characterized by a lipid-rich atheromatous core, which is infiltrated by macrophages. There is a correlation between the number of infiltrating macrophages and the severity of symptoms in acute myocardial infarction [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In contrast, infiltration by macrophages is rarely observed in stable plaques.</p>
<p id="Par20">
Macrophages are active in energy metabolism. Therefore, FDG-PET is a promising tool for the detection of vulnerable plaques, depending on the extent of macrophage infiltration.</p>
</sec>
<sec id="Sec11">
<title>Uptake of FDG in Vulnerable Plaques</title>
<p id="Par21">Thus far, numerous clinical
and nonclinical studies have investigated the use of FDG for the imaging of vulnerable plaques. In 1994, Kubota et al. demonstrated that FDG accumulated more in macrophages than in tumor cells [<xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, it is assumed that vulnerable plaques can be detected depending on the rate of macrophage infiltration in the plaque. In the early 2000s, several clinical studies suggested that it is possible to detect atherosclerosis, according to the level of inflammation [<xref ref-type="bibr" rid="CR26">26</xref>â<xref ref-type="bibr" rid="CR28">28</xref>]. Notably, through histological analysis of symptomatic carotid artery plaques, Rudd et al. reported the co-localization of [<sup>3</sup>H]FDG and macrophages [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
<p id="Par22">The investigators examined the relationship between the degree of macrophage infiltration and accumulation of FDG in Watanabe heritable hyperlipidemic (WHHL) rabbitsâan arteriosclerotic animal modelâ, and explored the possibility of detection of vulnerable plaques using FDG-PET [<xref ref-type="bibr" rid="CR29">29</xref>]. The atherosclerotic plaques were detected by FDG-PET (Fig. <xref ref-type="fig" rid="Fig5">1.5</xref>). In WHHL rabbits, thickening of the intima and infiltration by macrophages was observed in all individuals. We examined the degree of macrophage filtration via histological analysis. The results showed that the FDG uptake and number of macrophages in the atherosclerotic lesions were strongly correlated (Fig. <xref ref-type="fig" rid="Fig6">1.6</xref>). However, there was no correlation between the degree of macrophage infiltration and that of intimal thickening. These results suggested that macrophages are responsible for the accumulation of FDG in atherosclerotic lesions, and vulnerable plaques may be detected through FDG-PET.<fig id="Fig5"><label>Fig. 1.5</label><caption><p>Fused PET-CT images of WHHL and control rabbits. The WHHL rabbit is an animal model of atherosclerosis. The pink arrowheads show the aortas. The aorta was clearly imaged using FDG in WHHL rabbits</p></caption><graphic id="MO5" xlink:href="477582_1_En_1_Fig5_HTML"></graphic></fig>
<fig id="Fig6"><label>Fig. 1.6</label><caption><p>Correlation between the uptake of FDG and the number of macrophages in the aortic segments of WHHL rabbits. The uptake of FDG was well correlated with the degree of macrophage infiltration. <italic>DUR</italic> differential uptake ratio</p></caption><graphic id="MO6" xlink:href="477582_1_En_1_Fig6_HTML"></graphic></fig>
</p>
<p id="Par23">Studies in humans have shown that the uptake of FDG into vulnerable plaques correlates with the infiltration by macrophages [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Immunohistochemical staining of macrophage marker CD68 revealed a strong correlation with FDG accumulation. It has also been reported that the incorporation of Matrix Metalloproteinase-1âan enzyme involved in the destabilization of plaquesâand FDG are strongly related [<xref ref-type="bibr" rid="CR32">32</xref>]. Tahara et al. reported correlations between the accumulation of FDG and waist circumference, hypertension, insulin resistance, lowering of high-density lipoprotein cholesterol, etc. [<xref ref-type="bibr" rid="CR33">33</xref>]. A recent study showed a correlation of FDG accumulation with C-reactive protein [<xref ref-type="bibr" rid="CR34">34</xref>]. The results of these studies indicate the prospect for the use of FDG-PET in arteriosclerosis-related diseases.</p>
</sec>
<sec id="Sec12">
<title>Foam Cell Formation and FDG Uptake</title>
<p id="Par24">
Foam cell formation is responsible for the vulnerability of plaques. Macrophages are recruited from blood monocytes
that enter through the endothelium (Fig. <xref ref-type="fig" rid="Fig7">1.7</xref>). Scavenger receptors on macrophages mediate the uptake of oxidized low-density lipoprotein (LDL) and cause the accumulation of LDL-derived cholesterol and foam cell formation. Foam cells release several proteases and cytokines, which lead to rupture of the plaques. We evaluated the effects of foam cell formation on the uptake of FDG [<xref ref-type="bibr" rid="CR35">35</xref>]. Macrophages were isolated from the peritoneum cavity of mice, and foam cells were induced by acetylated LDL. The accumulation of FDG was increased via foam cell formation. However, the uptake was decreased to the level of control, following the complete differentiation into foam cells. The activity of hexokinase was changed in parallel with the uptake of FDG, i.e., higher activity was observed 24Â h after acetylated-LDL loading versus the control condition. Of note, the observed changes in glucose-6-phosphatase activity and glucose transporter 1 expression were not parallel to the uptake of FDG. This suggests that FDG-PET
detects the early stage of foam cell formation in atherosclerosis, depending on the activity of hexokinase. Moreover, using microautoradiography (ARG) in WHHL rabbits, it has been shown that the degree of infiltration by foamy macrophages in atherosclerotic lesions relates to the uptake of [<sup>3</sup>H]FDG [<xref ref-type="bibr" rid="CR36">36</xref>].<fig id="Fig7"><label>Fig. 1.7</label><caption><p>Scheme of the development of vulnerable atherosclerotic plaques. Monocytes differentiate into macrophages, and foam cells are formed through stimulation of a scavenger receptor by oxidized low-density lipoprotein (ox-LDL)</p></caption><graphic id="MO7" xlink:href="477582_1_En_1_Fig7_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec13">
<title>Polarization of Macrophages and Uptake of FDG</title>
<p id="Par25">Recent studies
have described that polarization of macrophages affects the development of atherosclerosis and rupture of plaques. Classically activated M1 macrophages are considered to possess the most proatherogenic phenotype and promote the destabilization of atherosclerotic plaques. In contrast, alternatively activated M2 macrophages possess anti-inflammatory properties and stimulate reparative processes, which lead to the stabilization of atherosclerotic plaques [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] (Fig. <xref ref-type="fig" rid="Fig8">1.8</xref>). Therefore, the detection of M1 macrophages may assist in predicting cardiovascular events with greater accuracy. In our investigation, M1 macrophages showed a 2.6-fold increased uptake of [<sup>3</sup>H]FDG versus M2 macrophages [<xref ref-type="bibr" rid="CR39">39</xref>]. Glucose transporter (GLUT)-1 and GLUT-3, which are major isoforms of a glucose transporter in macrophages, were significantly upregulated in M1 macrophages versus M2 macrophages. Furthermore, hexokinases 1 and 2 were significantly upregulated in M1 macrophages versus M2 macrophages. In contrast, the expression of glucose-6-phosphatase was significantly downregulated in M1 macrophages versus M2 macrophages. In vivo studies showed accumulation of [<sup>14</sup>C]FDG in the plaques and elevation of M1 markers (i.e., <italic>inducible nitric oxide synthase</italic>, interleukin-1b, and chemokine receptor 7). These results suggest that [<sup>18</sup>F]FDG-PET
dominantly visualizes the M1 macrophage-infiltrated areas.<fig id="Fig8"><label>Fig. 1.8</label><caption><p>Polarization of macrophages in vulnerable atherosclerotic plaques. M1 macrophages promote the destabilization of plaques, whereas M2 macrophages lead to the stabilization of plaques</p></caption><graphic id="MO8" xlink:href="477582_1_En_1_Fig8_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec14">
<title>Monitoring of theÂ Therapeutic Effect</title>
<p id="Par26">To date, numerous drugs
have been developed for the treatment of atherosclerosis. The therapeutic effects of these agents are usually monitored by determining the levels of lipids in the blood. However, lipid-lowering therapy does not always lead to the stabilization of vulnerable plaques. Several statins may effectively reduce the levels of cholesterol in the plasma; however, they do not decrease the degree of macrophage infiltration [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Thus, merely monitoring the levels of lipids in the plasma is not sufficient to determine the therapeutic effect of drugs. Macrophage infiltration plays an essential role in the rupture of plaques. Therefore, the administration of pharmacological therapy that reduces macrophage infiltration is required to stabilize the vulnerable plaques. Considering the individual differences in the stabilization of plaques induced by such drugs, monitoring the therapeutic effect in each individual plaque is important to accurately assess the effect.</p>
<p id="Par27">Using probucol as a therapeutic drug in WHHL rabbits, we investigated the usefulness of FDG-PET for the monitoring of therapies that target vascular inflammation. In a number of animal studies, the lipid-lowering effect of probucol was moderate, and the drug did not decrease the levels of cholesterol in the plasma [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. However, probucol can reduce the macrophage-rich plaques even in advanced atherosclerotic lesions [<xref ref-type="bibr" rid="CR43">43</xref>]. In the present study, the uptake of FDG was significantly decreased in the probucol group versus the pretreatment period (Fig. <xref ref-type="fig" rid="Fig9">1.9</xref>). However, there was no difference in the levels of cholesterol in the plasma between the probucol and control groups [<xref ref-type="bibr" rid="CR44">44</xref>]. A large number of macrophages
was observed at the initiation of the study. Nevertheless, treatment with probucol for 6Â months resulted in diminished macrophage infiltration (Fig. <xref ref-type="fig" rid="Fig10">1.10</xref>). Notably, the ratio of the intima to the whole cross-sectional area was not affected by treatment with probucol. Hence, the observed decrease in the uptake of FDG was attributed to the decrease in the number of infiltrating macrophages. Collectively, these studies showed that the therapeutic effect of probucol was successfully monitored by FDG-PET independently of the cholesterol-lowering effect.<fig id="Fig9"><label>Fig. 1.9</label><caption><p>Time course of the uptake of FDG in the aortas of WHHL rabbits over the treatment period. After 3Â months of treatment with probucol, the uptake of FDG (SUV) decreased in all treated rabbits. In contrast, the SUV remained constant or increased in control rabbits</p></caption><graphic id="MO9" xlink:href="477582_1_En_1_Fig9_HTML"></graphic></fig>
<fig id="Fig10"><label>Fig. 1.10</label><caption><p>Typical histological images of AzanâMallory-stained and macrophage immunohistochemically stained slices. Green arrow heads indicate macrophages. Treatment with probucol resulted in diminished macrophage infiltration</p></caption><graphic id="MO10" xlink:href="477582_1_En_1_Fig10_HTML"></graphic></fig>
</p>
<p id="Par28">These results demonstrated the usefulness of FDG-PET for drug development, and numerous clinical studies have been performed [<xref ref-type="bibr" rid="CR45">45</xref>â<xref ref-type="bibr" rid="CR49">49</xref>]. Tahara et al. conducted one of the initial clinical trials, showing that the therapeutic effect of simvastatin was successfully monitored by FDG-PET [<xref ref-type="bibr" rid="CR50">50</xref>]. In 2011, the results of the first clinical multicenter study investigating the efficacy of dalcetrapib against atherosclerotic disease via a novel noninvasive multimodality imaging technique (dal-PLAQUE) were reported. Of note, FDG-PET was used to evaluate the level of vascular inflammation [<xref ref-type="bibr" rid="CR51">51</xref>]. Moreover, in the dal-PLAQUE study, the relationship between serum inflammatory
biomarkers and plaque inflammation was also assessed using FDG-PET [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
</sec>
<sec id="Sec15">
<title>Comparison with Other PET Tracers</title>
<p id="Par29">Recently, several PET imaging tracersâapart from FDGâhave been reported for the imaging of vulnerable plaques. For example, [<sup>11</sup>C]choline and [<sup>18</sup>F]fluoromethylcholine are used for the detection of increased cell proliferation in the plaques [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In addition, [<sup>11</sup>C]PK11195 is used to detect translocator protein (TSPO) on macrophages [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Moreover, [<sup>68</sup>Ga]DOTATOC and [<sup>68</sup>Ga]DOTATATE are used to determine the expression of somatostatin receptor subtype 2 on macrophages [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Furthermore, [<sup>18</sup>F]FMISO is used for the detection of hypoxia around the neovascularization area near the plaques [<xref ref-type="bibr" rid="CR59">59</xref>], while [<sup>18</sup>F]NaF is used for the detection of calcification [<xref ref-type="bibr" rid="CR60">60</xref>â<xref ref-type="bibr" rid="CR63">63</xref>]. Recently, the Î²-amyloid imaging agent [<sup>18</sup>F]Flutemetamol showed specific accumulation in human carotid plaques, especially in amyloid beta-positive areas [<xref ref-type="bibr" rid="CR64">64</xref>].</p>
<p id="Par30">Among these tracers, [<sup>18</sup>F]NaF is considered a promising probe for the detection of atherosclerosis, and several comparison studies with FDG have been performed. The results of these studies showed that the area of accumulation differs between FDG and [<sup>18</sup>F]NaF [<xref ref-type="bibr" rid="CR65">65</xref>â<xref ref-type="bibr" rid="CR67">67</xref>]. The accumulation of [<sup>18</sup>F]NaF in atherosclerotic plaques depends on the level of calcification [<xref ref-type="bibr" rid="CR68">68</xref>]. The [<sup>18</sup>F]NaF-positive area does not completely match with the CT-positive area, and it is thought that [<sup>18</sup>F]NaF accumulates in the early stage of calcification (i.e., microcalcification) [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Since target molecules are different among these tracers, comparison study should be important to elucidate the specificity of these tracers for the different stages of atherosclerosis progression. This may assist in understanding the mechanism of plaque progression and provide important insight into therapy aimed toward the stabilization of plaques.</p>
</sec>
</body>
</sub-article>
<sub-article article-type="research-article" id="Sec16">
<front-stub>
<title-group>
<article-title>PET Imaging in Animal Model of Neuroinflammation 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Bin</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar4">
<title>Abstract</title>
<p id="Par31">Neuroinflammation is a general event in acute and chronic neurodegenerative disorders. Based on the critical role of neuroinflammation characterized by glial activation in neuropathogenesis, in vivo imaging with positron emission tomography (PET) is required in clinical and preclinical studies for the purposes of elucidation of pathogenesis and novel treatment development, because it is commonly available in human and experimental animal models. As a most widely used imaging biomarker for neuroinflammation, 18Â kDa translocator protein (TSPO) imaging has been performed in a large number clinical and preclinical studies. Neuropathology-associated TSPO induction has been generally detected in various neurodegenerative animal models with acute and chronic neuroinflammation. However, studies with human subjects showed confusing results likely due to ineffectiveness of the tracers used or impediment of non-microglial TSPO expression in human diseased brains. Based on the above reasons, recently, alternative molecular targets for microglia imaging instead of TSPO have been proposed. Colony-stimulating factor 1 receptor (CSF1R) is a promising candidate because of its highly specific expression in microglia in the central nervous system (CNS). Purinergic receptors P2X7R and P2Y12R have been proposed as imaging biomarkers of M1 and M2 phenotype microglia, respectively. Several PET tracers for these non-TSPO biomarkers have been developed, and some of them showed positive results in animal models. However, more exploratory work is needed for further application in human subjects.</p>
<p id="Par32"><bold>Keywords</bold>:âNeurodegenerative disorders, Neuroinflammation, Glial activation, In vivo imaging, 18Â kDa translocator (TSPO), Colony-stimulating factor 1 receptor (CSF1R)</p>
</sec>
<sec id="Sec17">
<title>Introduction</title>
<p id="Par33">
Neuroinflammation is characterized by glial activation, which would lead to an increase in the inflammatory factor level in the CNS. Microglia are a collection of glial cells that act as the first and main form of active immune defense in the CNS. Accordingly, its activation is considered to trigger neuroinflammation, and PET tracers bound to active microglia are used for imaging of neuroinflammation. Therefore, molecules exclusively expressed in microglia have the potential to be molecular targets for neuroinflammation. Because imaging with PET is a commonly available technology for human subjects and experimental animal models, numerous PET tracers have been developed for visualization of microglia in living brains. Moreover, increasing evidence has indicated that microglial activation is heterogeneous, and can be categorized into two opposite types: pro-inflammatory (M1) and anti-inflammatory (M2) microglial phenotypes. PET imaging tracers that bind to either general or phenotype-specific microglia are required for studies of neurodegenerative disorders. PET imaging in animal models is an indispensable step for the development and clinical application of PET tracers, as it will provide predictive evidence for tracer utility in human subjects. More importantly, it can easily provide a direct comparison between PET images and histopathology, which is usually difficult in human studies. PET imaging in animal models would supplement the weak points of human studies and provide interpretation for imaging in human subjects.</p>
</sec>
<sec id="Sec18">
<title>Current Standard of Neuroinflammation Imaging</title>
<p id="Par34">18Â kDa Translocator protein (TSPO) is a housekeeping protein in microglia and is greatly induced in active microglia in response to neural injury. PET tracers with high affinity for TSPO are the most widely used for neuroinflammation imaging. Tracers have been developed for TSPO imaging for several decades, including typical first-generation tracer <sup>11</sup>C-PK11195 and second-generation tracer <sup>11</sup>C-DAA1106 [<xref ref-type="bibr" rid="CR70">70</xref>]. Major parts of these tracers enable the visualization of microglial activation in acute neuroinflammation models triggered by acute events like traumatic brain injury, ischemia, and excitotoxic damages. A longitudinal PET imaging study has shown a continuing increased TSPO PET tracer uptake in a mouse model of mesial temporal lobe epilepsy induced by unilaterally intracranial kainic acid injection. The radioactivity uptake reached a peak at 7Â days, mostly related to microglial activation. After 14Â days, reactive astrocytes provided a major binding site for TSPO tracer [<xref ref-type="bibr" rid="CR71">71</xref>]. The finding of phase-dependent TSPO expression in subtypes of glial cells might contribute to the identification of optimal treatment windows in further clinical studies [<xref ref-type="bibr" rid="CR71">71</xref>]. Chronic neuroinflammation is usually observed in many chronic neurodegenerative disorders such as Alzheimerâs disease (AD), amyotrophic lateral sclerosis (ALS), and non-AD tauopathies. Most animal models of chronic neurodegenerative disorders are genetically modified mouse models. Authors have clearly demonstrated glial activation in response to accumulation of amyloid aggregates and treatment with the aid of TSPO-PET, indicating the utility of neuroinflammation imaging in monitoring of pathogenesis (Fig. <xref ref-type="fig" rid="Fig11">1.11</xref>). Amyloid accumulation is the earliest pathological change in the brain with AD, followed by tau aggregation and glial activation. Glial activation is predominantly concentrated around neuritic plaques, not diffuse plaques [<xref ref-type="bibr" rid="CR72">72</xref>]. More clinical studies have reported increased TSPO tracer accumulation in temporoparietal, entorhinal, and cingulate cortex rather than frontal cortex with rich diffuse plaques and poor neuritic plaques, partially supporting such observation, while a considerable number of studies failed to detect an increase in TSPO expression level [<xref ref-type="bibr" rid="CR73">73</xref>]. The amyloid plaques accumulated in the amyloid precursor protein (APP) model are dense-core plaques, around which there are abundant activated glial cells and TSPO expression, indicating a similar glial response between neuritic and dense core plaques. However, immunohistochemical analysis showed that active astrocytes have provided the majority of binding sites for TSPO tracer in the APP model [<xref ref-type="bibr" rid="CR74">74</xref>], while microglia around neuritic plaques expressed abundant TSPO [<xref ref-type="bibr" rid="CR75">75</xref>]. This distinction between species concerning glial characteristics might be attributable to neurodegenerative tau pathologies, which exist in AD but are uncommon in the APP model. In vivo TSPO imaging also demonstrated increased TSPO expression accompanied by tau-related atrophic brain in another model of AD mimicking the tau-related pathologies (Fig. <xref ref-type="fig" rid="Fig11">1.11</xref>) [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. Considering that predominant microglial TSPO expression and age-dependent brain atrophy in these tauopathy models mimicking tau-related pathologies are consistent with the condition in AD patient brains, neuroinflammation imaging in tauopathy models might well reflect the actual situation of pathologies in human subjects. Based on the fact that in vivo imaging for amyloid and tau, as well as TSPO have been available for clinical and preclinical studies, multiple tracer imaging enables the clarification of the mutual relationship between these AD-related pathologies. For example, longitudinal in vivo imagings with TSPO-PET (<sup>18</sup>F-FEDAA1106) and amyloid-PET (<sup>11</sup>C-PiB) have captured the increased level of neuroinflammation triggered by AÎ² immunotherapy, which greatly reduced amyloid accumulation in an identical APP model over the course of treatment (Fig. <xref ref-type="fig" rid="Fig12">1.12</xref>) [<xref ref-type="bibr" rid="CR77">77</xref>]. TSPO-PET in combination with tau-PET (<sup>11</sup>C-PBB3) in two tauopathy models showed that neuroinflammation was induced by two different tau aggregates (PBB3-positive and -negative) and thereby accelerated tau-mediated neuron damage via a distinct molecular mechanism [<xref ref-type="bibr" rid="CR78">78</xref>]. These studies provide experimental evidence for neuroinflammation-targeting therapeutic strategy. Similarly, TSPO tracer signals were also increased in lesioned brain regions in a mouse model of ALS, being consistent with microglial immunostaining [<xref ref-type="bibr" rid="CR79">79</xref>]. In contrast, the results from Parkinsonâs disease (PD) animal models look more complicated. PD animal models are relatively easy to prepare by treating the animals with neurotoxins such as methamphetamine and 6-hydroxydompaine (6-OHDA). Methamphetamine-induced degeneration of dopaminergic neuron terminals did not trigger TSPO-positive gliosis [<xref ref-type="bibr" rid="CR74">74</xref>], while 6-OHDA induced degeneration of dopaminergic neurons in either striatum or substantia nigra and increased the TSPO tracer signal [<xref ref-type="bibr" rid="CR80">80</xref>]. Interestingly, most of the clinical PET studies found no increase in the level of TSPO expression in the striatal regions of PD patients [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] despite severe dopaminergic degeneration in these regions, supporting the proposal that TSPO imaging is inapplicable to monitoring the degeneration of nonmyelinated nerve [<xref ref-type="bibr" rid="CR74">74</xref>].<fig id="Fig11"><label>Fig. 1.11</label><caption><p>TSPO-PET in AD mouse models mimicking amyloid and tau pathologies. Representative merged coronal brain images of T2-weighted MR, TSPO-PET and merged images showed that tracer binding was greatly increased in transgenic mice (Tg) of APP and tauopathy models mimicking amyloid (22-month-old) and tau (12-month-old) pathologies, respectively, compared with respective age-matched non-transgenic littermate mice (non-Tg). No obvious brain atrophy was observed in hippocampi of APP model as well as non-Tg mice (white arrows), while tauopathy model showed overtly atrophic hippocampi (white arrowheads). Red arrowheads indicated enlarged ventricles due to the hippocampal atrophy. Unpublished data</p></caption><graphic id="MO11" xlink:href="477582_1_En_1_Fig11_HTML"></graphic></fig>
<fig id="Fig12"><label>Fig. 1.12</label><caption><p>Monitoring of anti-AÎ² effect and neuroinflammation in amyloid immunotherapy. (<bold>a</bold>) AÎ² immunotherapy was performed in APP model mice by intracranial injection of a therapeutic anti-AÎ² antibody into the right hippocampus, and equivalent amount of vehicle was injected into the contralateral hippocampus as control. (<bold>b</bold>) APP model mice received repeated PET scans before (baseline) and after (1- and 2-week) treatment. Representative images of amyloid- and TSPO-PET merged with MRI brain template in an APP mouse showed that AÎ² immunotherapy greatly reduced amyloid accumulation (amyloid-PET) and induced an increase in TSPO expression (TSPO-PET) around the region treated by antibody (white arrowheads), but not vehicle. (Data were modified from ref. [<xref ref-type="bibr" rid="CR3">3</xref>])</p></caption><graphic id="MO12" xlink:href="477582_1_En_1_Fig12_HTML"></graphic></fig>
</p>
<p id="Par35">Quantitative PET studies require that the <ext-link ext-link-type="uri" xlink:href="http://www.turkupetcentre.net/petanalysis/input_function.html">input function</ext-link>, representing cumulative availability of authentic radiotracer in arterial plasma, is measured in case of the absence of ideal reference tissue. Because of the constitutive expression of TSPO in the whole brain, blood collection is needed for calculating the binding potential. However, this usually faces technical difficulties in the actual operation for the small mouse body. So the brain regions without pathological changes, such as cerebellum in rTg4510 mouse [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR78">78</xref>] or striatum in PS19 mouse [<xref ref-type="bibr" rid="CR72">72</xref>], are used as reference tissue when reference-tissue models are used. Although it will lead to underestimation of the binding potential due to constitutive low-level TSPO expression in reference regions, such analysis can provide relatively stable results compared to the percentage of injection dose, which is greatly affected by body weight, metabolic capacity, or other factors. Another issue is a concern for the partial volume effect due to the small volume of the region of interesting (ROI) in the case of mouse. This makes it difficult to correctly measure the radioactivity in certain subregions of mouse brain. The use of rat and nonhuman primate models is an alternative, but selectable neurodegenerative models are limited compared to mouse, as most models with pathologies of chronic neurodegenerative disorders, such as AD, ALS, and non-AD tauopathies [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>], are genetically modified murine models. Despite the fact that TSPO-PET successfully captured neuroinflammation in various animal models with acute and chronic neuroinflammation, the results in patients with chronic neuroinflammation seemed more complicated [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. One of the reasons is that a TSPO polymorphism (rs6971) greatly influences the affinity of a large majority of TSPO tracers in a tracer-dependent manner [<xref ref-type="bibr" rid="CR85">85</xref>]. Another possible reason is the differing cellular distribution of TSPO expression. Recent studies have shown that TSPO expression is not limited to microglia. Other brain components, for example, astrocytes and vascular endothelial cells, also express TSPO. Some studies have demonstrated dominant induction of TSPO expression in active astrocytes in a neuropathological type-dependent and phase-dependent manner [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Vascular expression of TSPO is also a factor that disturbs microglial TSPO imaging. Although no study has quantitatively measured the influence of vascular TSPO on tracer binding, inclusion of the additional vascular component in the modified reference-tissue model amplified the binding potential in AD more than in control by decreasing tracer binding to the vasculature in the disease cohort or was better correlated to brain TSPO mRNA [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. As few studies have focused on changes in vascular TSPO expression in diseased brains, determining which is responsible for the changes in TSPO tracer binding in diseased brains is a complicated issue. Further studies in combination with postmortem analyses or microglial TSPO-specific or vascular TSPO-specific knockout animals are desirable.</p>
</sec>
<sec id="Sec19">
<title>Alternative Molecular Targets for Microglia Imaging</title>
<p id="Par36">CSF1R is a novel imaging biomarker
for microglia by its exclusive expression in microglia in the CNS [<xref ref-type="bibr" rid="CR88">88</xref>]. Recently, Horti et al. reported a newly developed PET tracer, <sup>11</sup>C-CPPC, for CSF1R imaging. <sup>11</sup>C-CPPC showed high initial brain uptake and rapid washout from brain in normal rodent brain, and increased accumulation in inflammatory brains of rodent and nonhuman primate models including LPS-injection and AD mouse models. In vitro autoradiogram showed higher binding in postmortem brains with AD compared to healthy control [<xref ref-type="bibr" rid="CR88">88</xref>]. These results support the concept that CSF1R is a suitable molecular target for microglia imaging. However, <sup>11</sup>C-CPPC binding is increased in whole brain regions, and is not limited to regions with lesions as exemplified by cerebellum in AD model and intracranial LPS injection model, and immunohistochemistry for active microglia and CSF1R expression to support imaging results was not provided. Another reported CSF1R imaging tracer, <sup>11</sup>C-AZ683, showed high affinity for CSF1R (KiÂ =Â 8Â nM) and &gt;250-fold selectivity over other kinases tested, but low brain uptake in rodents and nonhuman primates limited its utility in living brains [<xref ref-type="bibr" rid="CR89">89</xref>]. Further examinations and improvements will be required for their clinical application. It is still unclear which microglia phenotypes predominantly express CSF1R because of the lack of data from immunohistochemical and biochemical analyses of the various neurodegenerative models.</p>
<p id="Par37">P2X7R and P2Y12R were considered to be predominantly expressed in M1 and M2 microglia phenotypes, respectively [<xref ref-type="bibr" rid="CR90">90</xref>]. In vitro autoradiographic analysis with <sup>11</sup>C-SMW139 showed high specific binding to viral vector-mediated human P2X7R expressed in rat brain, but no increase in binding was detected in postmortem brain with AD
compared to healthy control [<xref ref-type="bibr" rid="CR91">91</xref>]. Specific binding of <sup>11</sup>C-GSK1482160 is also detectable in P2X7R-overexpressing samples under in vitro condition [<xref ref-type="bibr" rid="CR92">92</xref>]. However, more evidence is required for both of the above two P2X7R tracers to prove their utilities in the living inflammatory brain. In vivo imaging with <sup>18</sup>F-JNJ-64413739 with high affinity and selectivity for P2X7R showed significant increase in tracer accumulation in the living LPS-induced neuroinflammatory brain, indicating its leading status among the current P2X7R tracers, while further work is needed to verify its utility in other types of neuroinflammation [<xref ref-type="bibr" rid="CR93">93</xref>â<xref ref-type="bibr" rid="CR95">95</xref>]. Villa et al. recently developed a carbon-11-labeled P2Y12R-binding compound. In vitro and ex vivo experiments with this radioactive compound showed increased binding in brain sections of mice treated with anti-inflammatory stimuli and decreased binding to brain sections of a murine stroke model and of a stroke patient [<xref ref-type="bibr" rid="CR96">96</xref>]. Immunohistochemistry and immunoblotting also supported the viewpoints that P2Y12R
is a biomarker for M2 phenotype microglia [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR96">96</xref>].</p>
</sec>
</body>
</sub-article>
<sub-article article-type="research-article" id="Sec20">
<front-stub>
<title-group>
<article-title>PET Imaging in Animal Models of Neuroinflammation 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Watabe</surname>
<given-names>Tadashi</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar5">
<title>Abstract</title>
<p id="Par38">Neuroinflammation is defined as inflammatory responses in the brain and spinal cord, and microglia and astrocytes are the mainly involved cells. Translocator protein (TSPO) has been the major target used in positron emission tomography (PET) to detect neuroinflammation with glial activation. In a preclinical study conducted in small animal models of brain ischemia and traumatic brain injury, a second-generation TSPO tracer [<sup>18</sup>F]DPA-714 PET was used for the evaluation of glial activation; the TSPO uptake was validated by comparison with the immunohistochemical findings of co-staining for TSPO and a microglial/macrophage or astrocyte maker. TSPO expression has also been reported in a model of Alzheimerâs disease, where TSPO-positive cells with two opposing roles were observed: neuroprotective astrocytes for reversible neuronal injury and detrimental microglia for irreversible neuronal injury. Recently, new targets have been identified in microglia, namely, cyclooxygenase-1 (COX-1) and purinergic receptor P2X7, which have been shown to be specifically expressed in the microglia. PET imaging targeting glial cells is a promising modality to characterize and monitor neuroinflammation longitudinally and with quantitative accuracy. The findings of preclinical models need to be confirmed in clinical studies beyond the limitation of animal model and the species differences between rodents and humans.</p>
<p id="Par39"><bold>Keywords</bold>:âNeuroinflammation, Glial activation, Translocator protein, Microglia, Astrocyte</p>
</sec>
<sec id="Sec21">
<title>Introduction</title>
<p id="Par40">
Neuroinflammation
is defined as inflammatory responses in the brain and spinal cord [<xref ref-type="bibr" rid="CR97">97</xref>]. It is observed in various types of brain diseases, including brain ischemia, traumatic brain injury, neurodegenerative disorders (Alzheimerâs disease, Parkinsonâs disease, etc.), and neuropsychiatric disorders (schizophrenia, autism spectrum disorder, etc.) [<xref ref-type="bibr" rid="CR98">98</xref>â<xref ref-type="bibr" rid="CR101">101</xref>]. In the central nervous system, two major glial cells are involved in the process of neuroinflammation, namely, microglia and astrocytes [<xref ref-type="bibr" rid="CR99">99</xref>]. To evaluate neuroinflammation in vivo, translocator protein (TSPO) has been the major target used in PET for the detection of neuroinflammation with glial activation [<xref ref-type="bibr" rid="CR102">102</xref>]. In glial cells, especially microglia, expression of TSPO is minimal in the resting state, but upregulated in the activated state [<xref ref-type="bibr" rid="CR103">103</xref>]. In previous studies, the first-generation TSPO-PET tracer, [<sup>11</sup>C]PK-11195, was mainly used to evaluate glial activation in small animals as well as humans. However, the evaluation using [<sup>11</sup>C]PK-11195 was found to be highly limited by the high nonspecific binding of the tracer [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]; therefore, over the last 10Â years, second-generation TSPO-PET tracers, such as [<sup>11</sup>C]DPA-713 and [<sup>18</sup>F]DPA-714, have been used because of their higher specific binding [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Although the binding affinity in humans has been shown to vary due to polymorphism, TSPO PET has been employed as an effective tool to visualize and quantify the degree of neuroinflammation associated with glial activation in preclinical studies conducted using animal models, including rodents [<xref ref-type="bibr" rid="CR106">106</xref>]. However, attention
needs to be paid to the inflammatory cells taking up TSPO, as TSPO expression is not only observed in activated microglia/macrophages but also in reactive astrocytes [<xref ref-type="bibr" rid="CR107">107</xref>].</p>
</sec>
<sec id="Sec22">
<title>Brain Ischemia Model</title>
<p id="Par41">For preclinical studies
using small animals, the middle cerebral artery occlusion (MACO) model was frequently used owing to its ease of handling for reperfusion and the abundance of accumulated evidence [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. Martin et al. evaluated the time-course of TSPO expression in the rat model of MCAO, in which transient focal ischemia was induced by 2-h intraluminal occlusion of the MCA, followed by reperfusion [<xref ref-type="bibr" rid="CR110">110</xref>]. [<sup>18</sup>F]DPA-714 PET showed significantly enhanced uptake on the ipsilateral side on days 7, 11, 15, and 21 after the induction of ischemia, with the peak observed on day 11. This finding corresponded to the immunohistochemical results of TSPO expression in the microglia/macrophages (TSPOÂ +Â /CD11b-positive cells) in the ischemic area. The authors also reported an increase in the number of TSPOÂ +Â /glial fibrillary acidic protein (GFAP)-positive cells in the lesioned area on day 21, with peaking of the number of such cells on day 30; this latter finding suggested the later involvement of reactive astrocytes showing TSPO expression. These results show that [<sup>18</sup>F]DPA-714 provides accurate quantitative information about the time-course of TSPO expression in the glial cells in experimental stroke. Figure <xref ref-type="fig" rid="Fig13">1.13</xref> shows the [<sup>11</sup>C]DPA-713 PET images and results of immunohistochemistry using antibodies for CD11b and GFAP in the rat model of MCAO 4Â days after transient ischemia for 1Â h followed by reperfusion. The areas of enhanced uptake of [<sup>11</sup>C]DPA-713 correspond to the areas showing high expression of CD11b, namely, areas containing a high number of activated microglia/macrophages. Immunohistochemistry showed reactive astrocytes, represented by cells showing GFAP expression, in the boundary of the ischemic area, which showed a low uptake of [<sup>11</sup>C]DPA-713 on PET images. In regard to the clinical significance of the findings in relation to treatment, Martin A et al. reported that uptake of [<sup>11</sup>C]DPA-713 in the ischemic lesion could be attenuated by administration of minocycline 1Â h after the reperfusion [<xref ref-type="bibr" rid="CR111">111</xref>]. Thus, TSPO PET
can also be used for monitoring the response to immunomodulatory therapy after brain ischemia.<fig id="Fig13"><label>Fig. 1.13</label><caption><p>(<bold>a</bold>) TSPO PET imaging of glial activation in the rat brain 4Â days after 1-h occlusion of the middle cerebral artery (left: T2-weighted image (T2WI) of MRI, middle: PET/MRI fusion, right: [<sup>11</sup>C]DPA-713 PET). High uptake was observed in the ischemic region corresponding to the hyperintensity lesion visualized on MRI (T2WI). (<bold>b</bold>) Comparison of TSPO PET and immunofluorescence images. Blue arrows indicate glial activation recognized on [<sup>11</sup>C]DPA-713 PET and red arrows indicate CD11b expression in microglia/macrophages or GFAP expression in astrocytes</p></caption><graphic id="MO13" xlink:href="477582_1_En_1_Fig13_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec23">
<title>Traumatic Brain Injury Model</title>
<p id="Par42">To evaluate traumatic brain injury (TBI) in small animals, a model of controlled cortical impact with a pneumatic impact device has been used for its high reproducibility and low mortality [<xref ref-type="bibr" rid="CR112">112</xref>]. We reported two peaks of [<sup>18</sup>F]DPA-714 uptake
in this model, namely, on day 7 in the cortical area and on day 21 in the thalamus after induction of the focal brain injury [<xref ref-type="bibr" rid="CR99">99</xref>]. The enhanced thalamic uptake was sustained until 14Â weeks after induction of the TBI (Fig. <xref ref-type="fig" rid="Fig14">1.14</xref>). Immunohistochemical analysis on day 7 revealed TSPO staining mainly co-localized with amoeboid CD11b-positive microglia/macrophages, and weakly with GFAP-positive astrocytes in the cortex; however, TSPO immunoreactivity was scarcely observed in the thalamus. Giemsa staining on day 7 revealed mononuclear cells, such as phagocytic macrophages, in the cortical area, although these cells were not detected in the ipsilateral thalamus. In the macrophage depletion study performed 1 week post-injury, the TSPO uptake was decreased in the cortex, but enhanced in the thalamus, suggesting that the cortical uptake was mainly attributable to uptake by phagocytic macrophages recruited from the bloodstream, while the thalamic uptake was most likely attributable to uptake by resident microglia. Electron microscopy at 4Â weeks post-TBI revealed morphologically activated microglia surrounding the degenerated axons and poorly myelinated neurons in the ipsilateral thalamus, indicating activation of the resident microglia and damage to the remaining neurons. TSPO expression was mainly evident in the activated microglia in the thalamus at 6Â weeks post-injury. Thus, by using [<sup>18</sup>F]DPA-714 PET, inflammatory migration could be detected from the cortex to the thalamus after focal brain injury. In addition, we also showed that depletion of myeloid-derived suppressor cells (MDSCs) was associated with enhanced cortical TSPO
uptake on day 7 after the induction of focal brain injury, by both immunohistochemistry and cellular phenotype analysis [<xref ref-type="bibr" rid="CR113">113</xref>]. This finding indicated that MDSCs may have strong immunosuppressive characteristics and limit inflammation and facilitate wound healing and recovery.<fig id="Fig14"><label>Fig. 1.14</label><caption><p>[<sup>18</sup>F]DPA-714 PET/CT images of mice after focal brain injury (static images obtained 20â30 min after radiotracer administration). Cortical uptake peaked at 1 week after induction of the injury and shifted to the ipsilateral thalamus after 3Â weeks. Arrows indicate glial activation in the ipsilateral side</p></caption><graphic id="MO14" xlink:href="477582_1_En_1_Fig14_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec24">
<title>Alzheimerâs Disease Model</title>
<p id="Par43">Postmortem analyses
of the brains of patients with Alzheimerâs disease (AD) have revealed neuroinflammatory changes, namely, accumulation of activated microglia and astrocytes, around senile plaques and fibrillary tau lesions [<xref ref-type="bibr" rid="CR114">114</xref>]. In this study, diffuse plaques in the brains of these patients were enveloped by a small number of Iba-1-positive microglia not expressing TSPO, while numerous microglia expressing both Iba-1 and TSPO were found to be in close contact with neuritic plaques. Thus, microglia expressing TSPO were recruited to fibrillar tau inclusions, but not to AÎ² deposits unaccompanied by tau pathology. Jin et al. reported that TSPO expression was observed, mainly in the astrocytes, in amyloid precursor protein 23 (APP23) transgenic (Tg) mice which show minimal neuronal loss, while TSPO-positive microglia were observed in the tangle-like tau lesions of tau Tg mice which show remarkable neuronal loss. They concluded that TSPO-positive astrocytes have protective roles against reversible neuronal injury, while TSPO-positive microglia have detrimental effects for irreversible neuronal injury [<xref ref-type="bibr" rid="CR115">115</xref>]. We evaluated TSPO expression in the APP23 Tg mice by immunohistochemistry (Fig. <xref ref-type="fig" rid="Fig15">1.15</xref>). TSPO immunoreactivity was observed around the amyloid beta (AÎ²) plaques and in reactive astrocytes (GFAP-positive). CD11b-positive microglia were relatively few in number as compared to the number of GFAP-positive astrocytes, consistent with the findings reported by Jin B et al. However, it should be borne in mind that no significant increase in the uptake of [<sup>18</sup>F]DPA-714 or of the amyloid tracer [<sup>11</sup>C]PIB was detected by in vivo PET performed prior to the immunohistochemistry in the same mice. Maier F et al. reported that AÎ² deposition was detectable earlier by histology than by amyloid PET in APP23 Tg mice, indicating the existence of a lower limit of sensitivity for the detection of AÎ² or neuroinflammation by PET [<xref ref-type="bibr" rid="CR116">116</xref>].<fig id="Fig15"><label>Fig. 1.15</label><caption><p>Immunofluorescence images of APP23 Tg mice (15Â months old) showing co-staining for (<bold>a</bold>) AÎ² and TSPO, (<bold>b</bold>) GFAP and TSPO, and (<bold>c</bold>) CD11b and TSPO. Left lower figure indicates low-magnification images of the brain and the pink-colored square indicates the evaluated area under high magnification. TSPO expression is observed around the amyloid beta (AÎ²) plaques, and GFAP-positive astrocytes show positive co-staining for TSPO. Microglia showing CD11b/TSPO co-staining are relatively few in number as compared to the number of astrocytes showing GFAP/TSPO co-staining. (<bold>d</bold>) [<sup>11</sup>C]PIB PET images of APP23 Tg mice as compared to wild-type (WT) mice; amyloid deposition is observed in the cortical region and the hippocampus, whereas no significant accumulation is observed in the WT mice</p></caption><graphic id="d30e2069" xlink:href="477582_1_En_1_Fig15a_HTML"></graphic><graphic id="d30e2070" xlink:href="477582_1_En_1_Fig15b_HTML"></graphic><graphic id="d30e2071" xlink:href="477582_1_En_1_Fig15c_HTML"></graphic></fig>
</p>
<p id="Par44">Shukuri et al. demonstrated that the expression of cyclooxygenase-1 (COX-1) in activated microglia and macrophages during neuroinflammation can be visualized by PET using [<sup>11</sup>C]ketoprofen methyl ester (KTP-Me), with immunohistochemical confirmation [<xref ref-type="bibr" rid="CR117">117</xref>]. One advantage of [<sup>11</sup>C]KTP-Me PET as compared to TSPO PET is that COX-1 is expressed only in activated microglia and not in astrocytes. They also reported that expression of COX-1 could be detected in 16- to 24-month-old APP23 Tg mice, in accordance with the time of histopathologic appearance of abundant AÎ² plaques and activated microglia [<xref ref-type="bibr" rid="CR118">118</xref>]. They also reported the possibility of treating AD by inhibition of COX-1 activity, as a treatment target, with nonsteroidal anti-inflammatory drugs (NSAIDS). Besides TSPO, PET
imaging of [<sup>11</sup>C]KTP-Me could also be a useful tool for monitoring COX-1 activity in activated microglia in neuroinflammation.</p>
</sec>
<sec id="Sec25">
<title>Other Models of Neuroinflammation</title>
<p id="Par45">Imamoto et al. showed that glial activation could be quantitatively imaged in the spinal cord of a rat model of neuropathic pain using [<sup>11</sup>C]PK11195 PET [<xref ref-type="bibr" rid="CR119">119</xref>]. It was suggested that high-resolution PET using TSPO-specific radioligands is useful for imaging to assess the role of glial activation, including neuroinflammatory processes, in the spinal cord. Belolli et al. reported increased enhanced TSPO uptake in a mouse model of multiple sclerosis induced by experimental autoimmune encephalomyelitis (EAE), with neuropathological confirmation of activated microglia [<xref ref-type="bibr" rid="CR120">120</xref>]. They concluded that combined use of TSPO-PET and MRI could provide complementary evidence of the ongoing disease process.</p>
<p id="Par46">Evaluation of neuroinflammation by PET in neuropsychiatric disorders, such as schizophrenia and autism spectrum disorder, has been limited to clinical studies, possibly due to the difficulty in establishing appropriate animal models mimicking the pathological condition of the patients.</p>
</sec>
<sec id="Sec26">
<title>New PET Tracer for Neuroinflammation</title>
<p id="Par47">As mentioned in Sect. <xref ref-type="sec" rid="Sec24">1.4.4</xref>, TSPO-positive glial
cells have both neurotoxic and neuroprotective effects. Two phenotypes of microglia have been recognized, namely, neurotoxic âM1â and neuroprotective âM2,â although it cannot be clearly separated as M1 or M2 [<xref ref-type="bibr" rid="CR121">121</xref>]. TSPO-positive microglia that accelerate tau deposition and neuronal deterioration are likely to be M1-polarized. When considering the treatment strategy for neurodegenerative disorders, it is important to detect the detrimental glial cells to suppress their function. Expression of the P2X7 receptor (purinergic receptor) has been reported to be observed in M1-polarized microglia, which could be a promising target for the detection of deleterious neuroinflammation [<xref ref-type="bibr" rid="CR122">122</xref>]. In contrast, expression of the P2Y12 receptor has been reported to be observed in the M2-like microglia [<xref ref-type="bibr" rid="CR123">123</xref>]. Recently, a PET radioligand for the P2X7 receptor was synthesized and its efficacy was evaluated in preclinical models. Finally, reproducible and dose-dependent receptor occupancy studies with a P2X7 receptor antagonist were performed using [<sup>18</sup>F]JNJ-54175446 in rhesus monkeys and humans [<xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. The usefulness of PET radioligands for the P2X7 receptor is not only limited to the diagnosis of neuroinflammation. [<sup>18</sup>F]PTTP, which is also a radioligand targeting the P2X7 receptor, has been shown to be potentially useful for the quantification of peripheral inflammation targeting macrophages and to distinguish inflammation from certain solid tumors [<xref ref-type="bibr" rid="CR126">126</xref>]. Other targets in microglia, such as sphingosine-1-phosphate receptor 1 (S1P1) or receptor for advanced glycation end products (RAGE), are also promising, but only in the preliminary stage of investigation at this moment [<xref ref-type="bibr" rid="CR127">127</xref>].</p>
</sec>
<sec id="Sec27">
<title>Conclusion</title>
<p id="Par48">Findings of PET imaging in animal models of neuroinflammation are summarized in this article. In preclinical studies, the pathology can be confirmed by immunohistochemistry or cellular phenotype analysis, as well as by comparison of the PET results. PET imaging targeting TSPO, COX-1, or P2X7 is a promising modality to characterize and monitor neuroinflammation longitudinally and with quantitative accuracy. However, it needs to be borne in mind that preclinical models do not always reflect the pathologies of the heterogeneous characteristics of patients in clinical practice. In addition, we should consider the species differences between rodents and humans. Any findings in preclinical models should be confirmed in clinical situations, which is one of the goals of translational research.</p>
<sec id="FPar6">
<title>Acknowledgements</title>
<p id="Par49">I would like to thank my collaborators: Dr. Sanae Hosomi (Department of Traumatology and Acute Critical Medicine) for the TBI study and Dr. Naoyuki Sato (Department of Clinical Gene Therapy) for the AD study.</p>
</sec>
</sec>
</body>
</sub-article>
<sub-article article-type="research-article" id="Sec28">
<front-stub>
<title-group>
<article-title>PET Imaging of Inflammation in theÂ Peripheral System with [18F]FEDAC, a Radioligand for Translocator Protein (18Â kDa)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Ming-Rong</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar7">
<title>Abstract</title>
<p id="Par50">Translocator protein (18Â kDa; TSPO) has a broad array of functions, such as regulation of cholesterol transport, steroid hormone synthesis, porphyrin and heme transport, apoptosis, cell proliferation, anion transport, mitochondrial function regulation, immunomodulation, and inflammation. TSPO is widely expressed in peripheral tissues, including the adrenal gland, kidney, lung, and heart. Because of its pharmacological actions related to inflammation, TSPO has become a useful biomarker for monitoring inflammation using positron emission tomography (PET) with a specific radiotracer. Herein, the author reviews the results of PET imaging with a TSPO-specific radiotracer [<sup>18</sup>F]FEDAC to noninvasively visualize and quantify TSPO in the peripheral tissues and monitor various inflammatory diseases, such as lung inflammation, nonalcoholic fatty liver disease, liver damage, liver fibrosis, multiple sclerosis, and rheumatic arthritis, in animal models. [<sup>18</sup>F]FEDAC-PET is a powerful tool for imaging TSPO and monitoring the progress of various inflammatory diseases of the peripheral system.</p>
<p id="Par51"><bold>Keywords</bold>:âTranslocator protein (18Â kDa), Lung inflammation, Nonalcoholic fatty liver disease, Liver damage, Liver fibrosis, Multiple sclerosis, Rheumatic arthritis</p>
</sec>
<sec id="Sec29">
<title>Introduction</title>
<p id="Par52">Translocator protein (18Â kDa; TSPO) is the critical component of a multimeric 140â200-kDa complex located in the outer mitochondrial membrane and enriched in the outer/inner mitochondrial membrane contact sites [<xref ref-type="bibr" rid="CR128">128</xref>]. TSPO
has broad functions related to the regulation of cholesterol transport, steroid hormone synthesis, porphyrin and heme transport, apoptosis, cell proliferation, anion transport, mitochondrial function regulation, immunomodulation, and inflammation [<xref ref-type="bibr" rid="CR128">128</xref>]. TSPO is widely distributed in the peripheral tissues, and the mRNA levels of TSPO are high in the adrenal glands, kidneys, spleen, skeletal muscle, heart, and lungs, and are low in the liver and brain. TSPO expression in blood cells has also been reported, in which phagocytic cells, including monocytes and polymorphonuclear neutrophils, show significantly higher TSPO expression than lymphocytes. It has been demonstrated that TSPO expression increases in inflammatory cells during the occurrence and progression of inflammation. Thus, TSPO has become a useful biomarker for monitoring inflammation using PET with a TSPO-specific radiotracer [<xref ref-type="bibr" rid="CR128">128</xref>].</p>
<p id="Par53">Since 2002, we have developed more than 10 PET radiotracers for the imaging of TSPO in preclinical studies and have translated four new TSPO radiotracers to clinical studies in our institute: [<sup>11</sup>C]DAA1106 [<xref ref-type="bibr" rid="CR129">129</xref>â<xref ref-type="bibr" rid="CR131">131</xref>], [<sup>18</sup>F]FEDAA1106 [<xref ref-type="bibr" rid="CR132">132</xref>â<xref ref-type="bibr" rid="CR134">134</xref>], [<sup>11</sup>C]AC-5216 [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>], and [<sup>18</sup>F]FEDAC [<xref ref-type="bibr" rid="CR137">137</xref>â<xref ref-type="bibr" rid="CR139">139</xref>]. Here, the author reviews their results from PET with [<sup>18</sup>F]FEDAC to noninvasively visualize TSPO in the peripheral tissues [<xref ref-type="bibr" rid="CR140">140</xref>] and monitor various inflammatory diseases, such as lung inflammation [<xref ref-type="bibr" rid="CR141">141</xref>], nonalcoholic fatty liver disease [<xref ref-type="bibr" rid="CR142">142</xref>], liver damage [<xref ref-type="bibr" rid="CR143">143</xref>], liver fibrosis [<xref ref-type="bibr" rid="CR144">144</xref>], multiple sclerosis [<xref ref-type="bibr" rid="CR145">145</xref>], and rheumatic
arthritis [<xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>], in animal models.</p>
</sec>
<sec id="Sec30">
<title>PET Imaging and Quantitative Analysis of TSPO in Rat Peripheral Tissues</title>
<p id="Par54">Using small-animal PET
with [<sup>18</sup>F]FEDAC, we performed TSPO imaging to quantify TSPO density in rat peripheral tissues, including heart, lungs, and kidneys [<xref ref-type="bibr" rid="CR140">140</xref>]. The in vivo distribution and kinetics of [<sup>18</sup>F]FEDAC were first examined and measured in rat peripheral tissues. Using the in vivo pseudo-equilibrium method, TSPO binding parameters (TSPO density [<italic>B</italic><sub>max</sub>] and dissociation constant [<italic>K</italic><sub>D</sub>]) and receptor occupancy were estimated in the peripheral tissues.</p>
<p id="Par55">PET study showed that the uptake of radioactivity was highly distributed in the lungs, heart, and kidneys, and the TSPO-enriched tissues could be clearly visualized after the injection of [<sup>18</sup>F]FEDAC (Fig. <xref ref-type="fig" rid="Fig16">1.16</xref>). The kinetics of this radiotracer in the tissues was moderate, which is suitable for determining the in vivo binding parameters and receptor occupancy. The <italic>B</italic><sub>max</sub> values of TSPO in the heart, lung, and kidney were 393, 141, and 158Â pmol/mL, respectively (Table <xref ref-type="table" rid="Tab1">1.1</xref>). The <italic>K</italic><sub>D</sub> values of [<sup>18</sup>F]FEDAC in the heart, lung, and kidney were 119, 36, and 123Â nM, respectively. After pretreatment with 5Â mg/kg Ro 5-4864 (a TSPO-selective ligand), about 90% of binding sites for TSPO in the heart and lung were occupied. In the kidneys, the TSPO binding was also completely inhibited by Ro 5-4864.<fig id="Fig16"><label>Fig. 1.16</label><caption><p>Representative coronal PET images of [<sup>18</sup>F]FEDAC in the isoflurane-anesthetized rat, which was placed in the prone position. PET images were generated by summating the whole scan (0â30Â min)</p></caption><graphic id="MO16" xlink:href="477582_1_En_1_Fig16_HTML"></graphic></fig>
<table-wrap id="Tab1"><label>Table 1.1</label><caption><p>TSPO density (<italic>B</italic><sub>max</sub>) and dissociation constant (<italic>K</italic><sub>D</sub>) of [<sup>18</sup>F]FEDAC measured by PET in peripheral tissues of living rats</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Tissue</th><th><italic>B</italic><sub>max</sub> (pmol/mL)</th><th><italic>K</italic><sub>D</sub> (nM)</th></tr></thead><tbody><tr><td>Heart</td><td>393 [323â529]<sup>a</sup>
</td><td>119 [89â180]<sup>a</sup>
</td></tr><tr><td>Lung</td><td>141 [112â205]<sup>a</sup>
</td><td>119 [26â61]<sup>a</sup>
</td></tr><tr><td>Kidney</td><td>158 [129â217]<sup>a</sup>
</td><td>123 [92â191]<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>95% Confidence intervals (<italic>n</italic>Â =Â 3)</p></table-wrap-foot></table-wrap>
</p>
<p id="Par56">Through this study, we demonstrated that [<sup>18</sup>F]FEDAC
is a useful PET tracer for TSPO imaging and quantitative analysis of TSPO expression in peripheral tissues. Therefore, [<sup>18</sup>F]FEDAC-PET can be used to study the TSPO function and evaluate the in vivo binding parameters and receptor occupancy of TSPO ligands. Subsequently, we used PET with [<sup>18</sup>F]FEDAC to determine if TSPO
increases in inflamed peripheral tissues of various animal models.</p>
</sec>
<sec id="Sec31">
<title>TSPO in Lung Inflammation</title>
<p id="Par57">TSPO
is highly expressed on the bronchial
and bronchiole epithelium, submucosal glands in intrapulmonary bronchi, pneumocytes and alveolar macrophages in human lungs. We performed PET imaging of lung inflammation with [<sup>18</sup>F]FEDAC and determined cellular sources that enrich TSPO in the lung [<xref ref-type="bibr" rid="CR141">141</xref>]. We prepared an acute lung injury model by using intratracheal administration of lipopolysaccharide (LPS) to rats. PET with [<sup>18</sup>F]FEDAC demonstrated that, in response to LPS treatment, the uptake of radioactivity increased in the lungs as the inflammation progressed (Fig. <xref ref-type="fig" rid="Fig17">1.17</xref>). Pretreatment with a TSPO-selective unlabeled ligand PK11195 significantly decreased the lung uptake of [<sup>18</sup>F]FEDAC because of competitive binding to TSPO. TSPO expression was elevated in the inflamed lung section and its level responded to the [<sup>18</sup>F]FEDAC uptake and severity of inflammation. The presence of TSPO was examined in the lung tissue using western blotting and immunohistochemical assays. The increase of TSPO expression was mainly found in the neutrophils and macrophages of inflamed lungs (Fig. <xref ref-type="fig" rid="Fig18">1.18</xref>).<fig id="Fig17"><label>Fig. 1.17</label><caption><p>Representative coronal PET lung images acquired between 0 and 30 min after injection of [<sup>18</sup>F]FEDAC. (<bold>a</bold>) control; (<bold>b</bold>) LPS-2Â h; (<bold>c</bold>) LPS-6Â h; (<bold>d</bold>) LPS-24Â h inducement; pretreatment with (<bold>e</bold>) PK11195 for LPS-6Â h; (<bold>f</bold>) PK11195 for LPS-24Â h</p></caption><graphic id="MO17" xlink:href="477582_1_En_1_Fig17_HTML"></graphic></fig>
<fig id="Fig18"><label>Fig. 1.18</label><caption><p>Double immunofluorescence labeling of ED1 (red) and TSPO (green) displayed as a two-channel image. The images demonstrated temporal alterations of TSPO expression in macrophages at 2Â h (<bold>d</bold>â<bold>f</bold>), 6Â h (<bold>g</bold>â<bold>i</bold>), and 24Â h (<bold>j</bold>â<bold>l</bold>) after LPS inducement, and in the control (<bold>a</bold>â<bold>c</bold>). Arrows indicate examples of cells doubly positive for ED1 and TSPO. (<bold>a</bold>â<bold>c</bold>) TSPO expression was observed in a few macrophages. (<bold>d</bold>â<bold>f</bold>) Several macrophages demonstrating TSPO immunoreactivity were observed in the alveolar spaces. (<bold>g</bold>â<bold>i</bold>, <bold>j</bold>â<bold>l</bold>) Numbers of macrophages with TSPO gradually increased over time. Scale bar: 20Â Î¼m</p></caption><graphic id="MO18" xlink:href="477582_1_En_1_Fig18_HTML"></graphic></fig>
</p>
<p id="Par58">Through this study, we demonstrated that PET with [<sup>18</sup>F]FEDAC
is a useful tool for imaging TSPO expression
and evaluating the progression of lung inflammation.</p>
</sec>
<sec id="Sec32">
<title>TSPO in Nonalcoholic Fatty Liver Disease</title>
<p id="Par59">Mitochondrial
dysfunction is responsible for liver damage and disease progression in nonalcoholic fatty
liver disease (NAFLD). TSPO, as a mitochondrial transmembrane protein, plays important roles in regulating mitochondrial function. We conducted PET with [<sup>18</sup>F]FEDAC to explore if TSPO could be used as an imaging biomarker of noninvasive diagnosis and staging of NAFLD [<xref ref-type="bibr" rid="CR142">142</xref>]. PET with [<sup>18</sup>F]FEDAC, CT, autoradiography, histopathology, and gene analysis were performed to evaluate and quantify TSPO levels and NAFLD
progression in methionine and choline-deficient diet-fed mice. The uptake of [<sup>18</sup>F]FEDAC increased with disease progression from simple steatosis to nonalcoholic steatohepatitis (NASH) (Fig. <xref ref-type="fig" rid="Fig19">1.19</xref>). A strong correlation was observed between [<sup>18</sup>F]FEDAC uptake ratio and NAFLD activity
score in the liver. The specific binding of [<sup>18</sup>F]FEDAC to TSPO in the NAFLD livers was demonstrated by competition experiments with the unlabeled TSPO-selective PK11195. Autoradiography and histopathology supported these PET imaging results. Further, there were greater mRNA levels of the functional macromolecular signaling complex composed of TSPO, compared to controls (Fig. <xref ref-type="fig" rid="Fig20">1.20</xref>).<fig id="Fig19"><label>Fig. 1.19</label><caption><p>Representative TSPO-PET/CT images of livers in MCD and control mice. (<bold>a</bold>) Summed TSPO-PET images of 0â30 min scanning in the 2, 4, 8Â weeks MCD-fed mice and the 8Â weeks normal-fed mice. [<sup>18</sup>F]FEDAC-PET signal gradually increased compared to the controls. (<bold>b</bold>) Average unenhanced CT images. Decreased attenuation value in the parenchyma was presented in all stages of NALFD. (<bold>c</bold>) TSPO-PET/CT fusion images. More severe pathologic injures took place in the areas of higher radioactivity accumulation</p></caption><graphic id="MO19" xlink:href="477582_1_En_1_Fig19_HTML"></graphic></fig>
<fig id="Fig20"><label>Fig. 1.20</label><caption><p>Ex vivo autoradiography and immunohistochemistry in liver sections of MCD and control mice (<italic>n</italic>Â =Â 6, respectively). (<bold>a</bold>) Ex vivo autoradiography demonstrated that radioactivity gradually increased in the livers with the time of MCD feeding. (<bold>b</bold>) Representing autoradiographic images of liver sections. (<bold>c</bold>) Double immunohistochemistry including TSPO (blue) and CD11b (orange). Preferential localization of TSPO indicated in the liver lesion sites, CD11b/TSPO active macrophages and lymphocytes increased in the MCD livers (Scale barsÂ =Â 500Â Î¼m). ââ<italic>P</italic>Â &lt;Â 0.01</p></caption><graphic id="d30e2885" xlink:href="477582_1_En_1_Fig20a_HTML"></graphic><graphic id="d30e2886" xlink:href="477582_1_En_1_Fig20b_HTML"></graphic></fig>
</p>
<p id="Par60">Through this study, we demonstrated that TSPO expression increased in NAFLD and was strongly correlated with NAFLD progression. TSPO as a specific molecular imaging biomarker could provide a novel tool for noninvasive, reliable, and quantitative
diagnosis
and staging of NAFLD.</p>
</sec>
<sec id="Sec33">
<title>TSPO in Liver Damage</title>
<p id="Par61">Liver damage
induced by drug toxicity
is an important problem for both medical doctors and patients. In this study, we noninvasively visualized acute liver damage using PET with [<sup>18</sup>F]FEDAC and determined cellular sources enriching TSPO expression in the liver [<xref ref-type="bibr" rid="CR143">143</xref>]. A mild acute liver damage model was prepared by a single intraperitoneal injection of cycloheximide (CHX) to rats. Treatment with CHX induced apoptosis and necrotic changes in hepatocytes with a slight neutrophil infiltration. The uptake of radioactivity in the ratsâ livers was measured with PET after injection of [<sup>18</sup>F]FEDAC. PET with [<sup>18</sup>F]FEDAC showed that the uptake of radioactivity increased in livers treated with CHX, compared to the controls (Fig. <xref ref-type="fig" rid="Fig21">1.21</xref>). The mRNA expression of TSPO was increased in the damaged livers compared to the controls, and the TSPO level was correlated with the [<sup>18</sup>F]FEDAC uptake
and severity of damage. TSPO expression in the damaged liver sections was mainly found in macrophages (Kupffer cells) and neutrophils, but not in hepatocytes (Fig. <xref ref-type="fig" rid="Fig22">1.22</xref>). The increase in expression of TSPO
mRNA was induced by an increase in the numbers of macrophages and neutrophils with TSPO in the damaged livers.<fig id="Fig21"><label>Fig. 1.21</label><caption><p>
Radioactivity and TSPO level in the livers of the control and CHX-treated rats. (<bold>a</bold>) Representative transverse PET liver images acquired between 0 and 30 min after injection of [<sup>18</sup>F]FEDAC. (<bold>b</bold>) Values of areas under time-activity curves. The values (AUC<sub>0â30 min</sub>; SUVÂ ÃÂ min, meanÂ Â±Â SEM, <italic>n</italic>Â =Â 4) were calculated from the time-activity curves between 0 and 30 min after the injection. A significant difference (<italic>P</italic>Â &lt;Â 0.05) was observed on the following comparisons, â: control vs. CHX 2Â h, 4Â h, and 6Â h. (<bold>c</bold>) Effect of CHX treatment on the mRNA expression of TSPO. A significant difference (<italic>P</italic>Â &lt;Â 0.05) was observed on the following comparisons, â: control vs. CHX treatment</p></caption><graphic id="MO21" xlink:href="477582_1_En_1_Fig21_HTML"></graphic></fig>
<fig id="Fig22"><label>Fig. 1.22</label><caption><p>Increased TSPO levels were expressed in macrophages in liver tissues after CHX treatment. Double immunofluorescence labeling of ED1 (red) and TSPO (green) in the centrilobular region (<bold>a</bold>) and the periportal region (<bold>b</bold>). <italic>CV</italic> central vein, <italic>PV</italic> portal vein. Scale bar: 100Â Î¼m</p></caption><graphic id="MO22" xlink:href="477582_1_En_1_Fig22_HTML"></graphic></fig>
</p>
<p id="Par62">Through this study, we demonstrated that PET imaging with [<sup>18</sup>F]FEDAC provided visible evidence that mild liver damage occurs through the enhanced TSPO signal in inflammatory cells, and that this method is a useful diagnostic tool in the early stages
of acute
liver damage.</p>
</sec>
<sec id="Sec34">
<title>TSPO in Liver Fibrosis</title>
<p id="Par63">Liver fibrosis
is the wound healing response
to chronic liver injury, which is caused by various factors. In this study, we evaluated the utility of TSPO as a molecular imaging biomarker for monitoring the progression of liver fibrosis in response to cirrhosis [<xref ref-type="bibr" rid="CR144">144</xref>]. To induce cirrhosis, carbon tetrachloride (CCl<sub>4</sub>) was administered to rats and the subsequent liver fibrosis was assessed. PET with [<sup>18</sup>F]FEDAC was used to noninvasively visualize liver fibrosis in vivo. PET scanning, immunohistochemical staining, ex vivo autoradiography, and quantitative reverse-transcription polymerase chain reaction were performed to elucidate the relationships among radioactivity uptake, TSPO level, and cellular source enriching TSPO expression in damaged livers. PET with [<sup>18</sup>F]FEDAC showed that the uptake of radioactivity in livers significantly increased after 2, 4, 6, and 8Â weeks of CCl<sub>4</sub> treatment (Fig. <xref ref-type="fig" rid="Fig23">1.23</xref>). Immunohistochemical analysis demonstrated that TSPO was primarily expressed in macrophages and liver stellate cells (HSCs). TSPO-expressing macrophages and HSCs increased with the progression of liver fibrosis (Fig. <xref ref-type="fig" rid="Fig24">1.24</xref>). The distribution of radioactivity from [<sup>18</sup>F]FEDAC was strongly correlated with TSPO
expression, and TSPO mRNA levels
increased with the severity of liver damage.<fig id="Fig23"><label>Fig. 1.23</label><caption><p>Accumulation of radioactivity and TSPO level in the livers of control and CCl<sub>4</sub>-treated rats. (<bold>a</bold>) Representative transverse PET/CT fusion images of rat livers. PET images were acquired between 0 and 30 min after injection of [<sup>18</sup>F]FEDAC. (<bold>b</bold>) Autoradiographic image of liver section 1Â h after injection of [<sup>18</sup>F]FEDAC is shown for control rat. (<bold>c</bold>) Autoradiographic image is shown for rat treated with CCl<sub>4</sub> for 6Â weeks. (<bold>d</bold>) Immunofluorescence staining of TSPO using the same sections as in (<bold>a</bold>) is shown for control rat. (<bold>e</bold>) Immunofluorescence staining and rats treated with CCl<sub>4</sub> for 6Â weeks. The distribution of radioactivity from [<sup>18</sup>F]FEDAC correlated well with the netlike appearance of TSPO expression in the hepatic lobules (<bold>c</bold>, <bold>e</bold>). Scale bar: 1 mm</p></caption><graphic id="MO23" xlink:href="477582_1_En_1_Fig23_HTML"></graphic></fig>
<fig id="Fig24"><label>Fig. 1.24</label><caption><p>Increased levels of TSPO expressed in HSCs and macrophages from liver tissues after CCl<sub>4</sub> treatment. Triple immunofluorescence labeling of TSPO (<bold>a</bold>, green), Î±-SMA (<bold>b</bold>, pink), CD11b (<bold>c</bold>, red), and DAPI (blue) in liver sections from control animals and animals treated with CCl<sub>4</sub> for 4, 6, or 8Â weeks (<bold>a</bold>â<bold>e</bold>). (<bold>d</bold> and <bold>e</bold>) Show merged images of (<bold>a</bold>) and (<bold>b</bold>) and of (<bold>a</bold>) and (<bold>c</bold>), respectively. The dotted line square in each slide (<bold>d</bold>, <bold>e</bold>) is enlarged and shown in the inset with DAPI. Arrowheads point to TSPO double-stained HSCs (a-SMA-positive cells). Arrows point to TSPO double-stained macrophages (CD11b-positive cells). Scale bar: 50Â Î¼m</p></caption><graphic id="MO24" xlink:href="477582_1_En_1_Fig24_HTML"></graphic></fig>
</p>
<p id="Par64">Through this study, we demonstrated that TSPO is a useful molecular imaging biomarker for monitoring the progression of liver fibrosis in response
to cirrhosis
with PET.</p>
</sec>
<sec id="Sec35">
<title>TSPO in Multiple Sclerosis</title>
<p id="Par65">Imaging
modalities
have the potential to monitor inflammation in order to guide treatment before significant functional impairment or irreversible cellular damage occurs in multiple sclerosis (MS). In this study, [<sup>11</sup>C]DAC, a carbon-11-labeled TSPO radiotracer derived from [<sup>18</sup>F]FEDAC, was used to evaluate neuroinflammation and quantify the therapeutic effects of experimental autoimmune encephalomyelitis (EAE), an animal model of MS [<xref ref-type="bibr" rid="CR145">145</xref>]. PET with [<sup>11</sup>C]DAC was used to visually assess neuroinflammation in EAE by measuring TSPO expression in the spinal cords; there was the maximal uptake on day 11 and 20 EAE rats with significant inflammatory cell infiltration, compared to controls, day 0 and 60 EAE rats (Fig. <xref ref-type="fig" rid="Fig25">1.25</xref>). Biodistribution studies and in vitro autoradiography confirmed the PET imaging results. Doubling immunohistochemical studies demonstrated the infiltration and expansion of CD4+ T cells and CD11b+ microglia; CD68+ macrophages caused the increase in TSPO levels visualized by [<sup>11</sup>C]DAC-PET. Furthermore, mRNA level analysis of the cytokines using quantitative reverse-transcription polymerase chain reaction revealed that TSPO+/CD4 T cells, TSPO+ microglia, and TSPO+ macrophages in EAE spinal cords were activated and secreted multiple pro-inflammation cytokines, which mediated the inflammation lesions of EAE. The EAE rats treated with an immunosuppressive agent FTY720 exhibited an absence of inflammatory cell infiltrates and displayed a faint radioactive signal, compared to the high accumulation in untreated EAE
rats (Fig. <xref ref-type="fig" rid="Fig26">1.26</xref>).<fig id="Fig25"><label>Fig. 1.25</label><caption><p>Representative PET images acquired by summed whole scan duration of 0â30 min after [<sup>11</sup>C]DAC injection. [<sup>11</sup>C]DAC-PET signal increased significantly in day 7, 11, and 20 EAE spinal cords</p></caption><graphic id="MO25" xlink:href="477582_1_En_1_Fig25_HTML"></graphic></fig>
<fig id="Fig26"><label>Fig. 1.26</label><caption><p>Reduced uptake of [<sup>11</sup>C]DAC in EAE by FTY720 treatment. (<bold>a</bold>) [<sup>11</sup>C]DAC-PET scans were performed at 11Â days EAE rats that treated or untreated with FTY720 (<italic>n</italic>Â =Â 8, respectively). Uptake of [<sup>11</sup>C]DAC was clearly increased only in day 11 untreated rats, uptake in FTY720-treated rats remained low and unchanged, similar to naÃ¯ve rats. Reduced uptake of [<sup>11</sup>C]DAC reflected the inhibition of neuroinflammation in EAE by FTY720 treatment. (<bold>b</bold>â<bold>d</bold>) H&amp;E staining of day 11 spinal sections indicated that rats with FTY720 treatment exhibited a complete absence of inflammatory cell infiltrates compared to the compressive inflammatory lesions in untreated rats</p></caption><graphic id="MO26" xlink:href="477582_1_En_1_Fig26_HTML"></graphic></fig>
</p>
<p id="Par66">Through this study, we demonstrated that [<sup>11</sup>C]DAC-PET imaging
is a useful tool for noninvasively monitoring the neuroinflammation
response and evaluating therapeutic interventions in EAE.</p>
</sec>
<sec id="Sec36">
<title>TSPO in Rheumatic Arthritis</title>
<p id="Par67">Rheumatoid arthritis (RA) is a chronic disease
characterized by systemic inflammation that results in the destruction of multiple articular
cartilages and bones. Activated macrophages have been known to play important roles in the pathogenesis of rheumatoid arthritis (RA). Cheon et al. evaluated the feasibility of [<sup>18</sup>F]FEDAC-PET in a murine RA model [<xref ref-type="bibr" rid="CR146">146</xref>]. In the collagen-induced arthritis (CIA) mice, joint swelling was apparent on day 26 after the first immunization, and the condition worsened by day 37. In these mice, the mRNA and protein expression of the TSPO increased in activated macrophages. The uptake of [<sup>18</sup>F]FEDAC in activated macrophages was greater compared to the uptake in nonactivated cells, which was inhibited by PK11195. The [<sup>18</sup>F]FEDAC uptake by arthritic joints increased early on (day 23), whereas [<sup>18</sup>F]FDG uptake did not (Fig. <xref ref-type="fig" rid="Fig27">1.27</xref>). However, [<sup>18</sup>F]FDG uptake by arthritic joints markedly increased at later stages (day 37) to a higher level than [<sup>18</sup>F]FEDAC uptake. The [<sup>18</sup>F]FEDAC uptake correlated weakly with the summed severity score, whereas the [<sup>18</sup>F]FDG uptake correlated strongly with the summed severity score. Histologic sections of arthritic joints demonstrated an influx of macrophages compared to that in normal joints (Fig. <xref ref-type="fig" rid="Fig28">1.28</xref>). Moreover, these indicated that PET imaging using [<sup>18</sup>F]FEDAC may be used as a predictor of the therapeutic effects caused by biological disease-modifying antirheumatic drugs that have anti-inflammatory actions to inhibit activated macrophages [<xref ref-type="bibr" rid="CR147">147</xref>].<fig id="Fig27"><label>Fig. 1.27</label><caption><p>(<bold>a</bold>) Coronal [<sup>18</sup>F]FEDAC PET/CT section of same CIA mouse on days 23 and 37, showing increased uptake in front and hind paws. (<bold>b</bold>) Coronal section of [<sup>18</sup>F]FDG PET/CT (<bold>a</bold>, <bold>b</bold>) in the same mouse. On day 23, uptake by joints was not observed before the onset of arthritis. On day 37, increased [<sup>18</sup>F]FDG uptake was observed for all four arthritic joints</p></caption><graphic id="MO27" xlink:href="477582_1_En_1_Fig27_HTML"></graphic></fig>
<fig id="Fig28"><label>Fig. 1.28</label><caption><p>Immunofluorescence staining for CD68 (red) and TSPO (green) in synovium of control and CIA joints. Merged images at far right show increased number and TSPO expression of CD68-positive macrophages, compared to controls</p></caption><graphic id="MO28" xlink:href="477582_1_En_1_Fig28_HTML"></graphic></fig>
</p>
<p id="Par68">Through these results, it was demonstrated that [<sup>18</sup>F]FEDAC
enabled the visualization of active inflammation sites in arthritic joints in a CIA model by targeting TSPO
expression in activated macrophages. The results suggest the potential usefulness of [<sup>18</sup>F]FEDAC-PET
imaging in the early phase of RA.</p>
</sec>
<sec id="Sec37">
<title>Conclusion</title>
<p id="Par69">[<sup>18</sup>F]FEDAC-PET is a powerful tool for visualizing TSPO and monitoring the progress of various inflammatory diseases of the peripheral system. The present studies will contribute to determination of the pathogenic progress and will be of use in evaluating the therapeutic effects of anti-inflammatory drugs. In future studies, we will perform or are performing PET imaging with [<sup>18</sup>F]FEDAC or other TSPO radiotracers to detect various inflammation in humans.</p>
<sec id="FPar8">
<title>Acknowledgements</title>
<p id="Par70">The author thanks Mr. Kumata, Ms. Hatori, Dr. Xie, Dr. Yanamoto, and Dr. Yamasaki in my group for their fruitful experiments and continuous outputs which contributed to this review.</p>
</sec>
</sec>
</body>
</sub-article>
<sub-article article-type="research-article" id="Sec38">
<front-stub>
<title-group>
<article-title>Role of Microglia in Neuroinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Suzuki</surname>
<given-names>Hiromi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sawada</surname>
<given-names>Makoto</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar9">
<title>Abstract</title>
<p id="Par71">At present, common diseases of CNS were often chronic and progressive which could affect the patientâs quality of life seriously. But the pathogenesis for most of them had not been fully understood and was no effective prevention or treatment. Certain pathological injury could cause cellular inflammatory response. Microglia, the first activated effector cells, played an important role in the immune defense process. Microglia had a two-way effect. On the one hand, activated microglia phagocytosed damaged cell debris and removed antigenic substances, and could release cytotoxic factors which would aggravate the injury of neuron. On the other hand, activated microglia may accumulate around damaged neurons and might induce neurotrophin-dependent protective activity. Therefore, to study the mechanism of microglia in the diseases of CNS and limit their effects on neuronal injury may help to retard the procession of some chronic disease and enhance the therapeutic effect of acute CNS diseases. Microglia are expected to become a new target for the treatment of neurodegenerative diseases and central nervous system diseases.</p>
<p id="Par72"><bold>Keywords</bold>:âMicroglia, Subtype, Cytokine, Toxic change, Neuroprotection</p>
<p id="Par73">
<bold>Abbreviations</bold>
<def-list><def-item><term>dbcAMP</term><def><p id="Par75">dibutyryl cyclic AMP</p></def></def-item><def-item><term>GM-CSF</term><def><p id="Par76">granulocyte-macrophage colony-stimulating factor</p></def></def-item><def-item><term>M-CSF</term><def><p id="Par79">macrophage colony-stimulating factor</p></def></def-item><def-item><term>MHC</term><def><p id="Par80">major histocompatibility complex</p></def></def-item><def-item><term>TGF</term><def><p id="Par82">transforming growth factor</p></def></def-item></def-list>
</p>
</sec>
<sec id="Sec39">
<title>Introduction</title>
<p id="Par84">
Neurodegenerative diseases such as Alzheimerâs disease and Parkinsonâs disease cause neuroinflammation including expression of MHC antigens and production of inflammatory cytokines. However, the condition changes greatly in relation to the onset and the formation of a pathological condition. Microglia, macrophage-like
cells in the central nervous system (CNS), are multifunctional cells; they play important roles not only in the neuro-inflammation but also in the development, differentiation, and maintenance of neural cells via their phagocytic activity and production of enzymes, cytokines, and trophic factors [<xref ref-type="bibr" rid="CR148">148</xref>].</p>
</sec>
<sec id="Sec40">
<title>Microglia Diversity</title>
<p id="Par85">Microglial cells
show a rather uniform distribution of cell numbers throughout the brain with only minor population in some brain regions. Their in situ morphologies, however, may vary markedly from elongated forms observed in apposition with neuronal fibers to spherical cell bodies with sometimes extremely elaborated branching. Human fetal microglia display heterogeneity in phenotype identified by CD68 [<xref ref-type="bibr" rid="CR149">149</xref>]. This heterogeneity gave rise to the hypothesis that these cells are differentially conditioned by their microenvironment and, therefore, also display specific patterns of differential gene expression. For example, mRNAs of TNF-alpha, CD4, and Fc gamma receptor II are differentially expressed in microglia isolated from different area of the brain [<xref ref-type="bibr" rid="CR150">150</xref>]. It has been reported that production of IL-12 [<xref ref-type="bibr" rid="CR151">151</xref>] and histamine [<xref ref-type="bibr" rid="CR152">152</xref>] are different in the subtypes of microglia. Furthermore, the subtypes of microglia show distinct acidification profiles by treatment with pepstatin A [<xref ref-type="bibr" rid="CR153">153</xref>] and selective clearance of oligomeric beta-amyloid peptide [<xref ref-type="bibr" rid="CR154">154</xref>]. The distinct phenotypes in activated forms of microglia might result from this heterogeneity.</p>
<p id="Par86">Although the origin of microglia is still controversial, resident microglia is thought to be of mesodermal origin, being derived from a bone marrow precursor cell [<xref ref-type="bibr" rid="CR155">155</xref>]. These cells or a lineage related to monocytes and macrophages may invade the CNS at an early embryonic stage to give rise eventually to typical process-bearing resident microglia [<xref ref-type="bibr" rid="CR155">155</xref>]. Like macrophages in other tissues, the growth and activation of microglia is regulated by macrophage colony-stimulating factor (M-CSF) [<xref ref-type="bibr" rid="CR156">156</xref>]. However, unlike macrophages, microglia are observed in macrophage-deficient mice [<xref ref-type="bibr" rid="CR157">157</xref>â<xref ref-type="bibr" rid="CR159">159</xref>], suggesting the possibility of the presence of M-CSF-independent populations.</p>
<p id="Par87">Despite the postulate that microglia arise from blood monocytes, microglia appear to display phenotypes differing from macrophages. In vivo, microglia do not normally express MHC class I and II [<xref ref-type="bibr" rid="CR160">160</xref>], CD14 [<xref ref-type="bibr" rid="CR161">161</xref>], or scavenger receptor I and II [<xref ref-type="bibr" rid="CR162">162</xref>]. Their appearance takes a ramified form [<xref ref-type="bibr" rid="CR160">160</xref>]. In contrast, monocytes and macrophages express these surface antigens absent in microglia and their shape is ameboidal [<xref ref-type="bibr" rid="CR160">160</xref>]. Like their in vivo counterparts, isolated microglia also differ from macrophages. Although cultured microglia are ameboidal, they can transform to a ramified form [<xref ref-type="bibr" rid="CR163">163</xref>]. Microglial cell proliferation is induced by conditioned medium from astrocyte-enriched cultures [<xref ref-type="bibr" rid="CR163">163</xref>]. Microglial production of interleukin (IL)-5 is stimulated by bioactive phorbol ester but not by interferon-Î³, while the opposite is there for macrophages [<xref ref-type="bibr" rid="CR164">164</xref>]. Microglia
do not constitutively express IL-2 receptors under normal culture conditions, as do monocytes and macrophages [<xref ref-type="bibr" rid="CR165">165</xref>]. Microglia express these receptors only after stimulation such as with lipopolysaccharide (LPS) [<xref ref-type="bibr" rid="CR165">165</xref>]. IL-2 increases viability and proliferation of lipopolysaccharide-stimulated microglia [<xref ref-type="bibr" rid="CR165">165</xref>], while macrophages respond to IL-2 by expressing IL-1, IL-6, and tumor necrosis factor Î± mRNAs, peroxide production, and microbicidal and tumoricidal activity [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. LPS, cyclosporin A, and FK506 downregulate expression of CD4 in microglia, but not in macrophages [<xref ref-type="bibr" rid="CR168">168</xref>]. Finally, bone marrow chimera experiments
have shown that resident microglia form highly stable pool of CNS cells displaying very little exchange with the bone marrow compartment [<xref ref-type="bibr" rid="CR169">169</xref>â<xref ref-type="bibr" rid="CR171">171</xref>]. These controversial observations suggest that microglia in the brain may be different from macrophages.</p>
<p id="Par88">Recently, we identified two distinct subpopulations of microglia in the normal mouse brain: type I and type II. Both types had similar phagocytic activity, but they showed distinct phenotypes such as cell-surface markers, mRNA expression, and growth factor dependency. Type I, but not type II, microglia expressed the hallmarks of microglia such as CD14 and C3b receptor, and production of interleukin 1Î². Type II microglia expresse surface markers for immature bone marrow cells, such as antigens against ER-MP12 and ER-MP20 antibodies, which are not detected in mature monocyte/macrophages. In addition, it also express one-tenth amount of mature cell markers compared to monocytes/macrophages. Therefore, type II microglia may arise from progenitor cells similar to immature bone marrow cells which migrate to the CNS during the early developmental stages then differentiate in the CNS; monocyte-differentiation out of bone marrow like extrathymic differentiation of T-cells [<xref ref-type="bibr" rid="CR172">172</xref>]. This suggests that the two distinct type of microglia arise from distinct origins. In addition, type I microglia exhibited M-CSF-dependent growth, while the type II were M-CSF-independent. A previous report suggested that alveolar macrophages are GM-CSF- but not M-CSF-dependent [<xref ref-type="bibr" rid="CR173">173</xref>]. These observations indicate that there are two distinct populations of microglia
which are probably of different origins and have different functions in the brain.</p>
</sec>
<sec id="Sec41">
<title>Microglia and Neuroinflammation</title>
<p id="Par89">The presence
of oxidative
stress and inflammatory activity is one of the significant pathological features of neuroinflammatory diseases [<xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]. It has been shown that the levels of cytokines such as tumor necrosis factor (TNF)-Î±, interleukin (IL)-1Î², and interferon (IFN)-Î³ are elevated in the substantia nigra of patients with Parkinsonâs disease [<xref ref-type="bibr" rid="CR176">176</xref>]. Since microglia are a principal source of these cytokines, the data support microglial involvement in the pathogenesis of neuroinflammatory diseases. However, the role of activated microglia is controversial. For example, the characteristic pathological features of the Parkinsonâs disease brain are a selective and progressive loss of dopamine neurons of the substantia nigra and their terminals in the caudate-putamen, along with focal accumulation
of activated microglia in the substantia nigra and caudate-putamen. The traditional view is that microglia act merely as scavengers and their activation is secondary to the neuronal damage. However, activated microglia have been observed in the limbic system and neocortex, where there are few or no degenerating neurons, in significantly higher numbers in PD brains than in brains from normal controls [<xref ref-type="bibr" rid="CR177">177</xref>].</p>
<p id="Par90">Activation of microglia has also been identified in the substantia nigra and/or striatum of parkinsonian animal models, such as l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism [<xref ref-type="bibr" rid="CR178">178</xref>, <xref ref-type="bibr" rid="CR179">179</xref>]. The link between microglia activation and selective neuronal vulnerability has led many researchers to suggest that microglia activity participates in neuronal demise. In this respect, microglial cytotoxicity may contribute to or even promote neuronal damage. Activated microglia are capable of releasing numerous cytotoxic agents, including proteolytic enzymes, cytokines, complement proteins, reactive oxygen intermediates, NMDA-like toxins, and nitric oxide [<xref ref-type="bibr" rid="CR148">148</xref>]. In fact, Î²-amyloid, the senile plaque-derived component found in Alzheimerâs disease, appears to elicit neurotoxic responses through the activation of microglia [<xref ref-type="bibr" rid="CR180">180</xref>]. However, this suggestion relies solely on in vitro data and as yet no evidence has been presented that indicates that activated microglia
destroy neurons
under in vivo conditions.</p>
</sec>
<sec id="Sec42">
<title>Existence of Nontoxic Activated Form of Microglia in theÂ Brain</title>
<p id="Par91">Recently we showed that highly activated microglia
treated with LPS may have neurotrophic potential toward dopamine neurons in neonatal mice administered MPTP [<xref ref-type="bibr" rid="CR181">181</xref>]. Tyrosine hydroxylase activity and the levels of dopamine and dihydroxyphenylacetic acid (DOPAC), as well as those of the pro-inflammatory cytokines IL-1Î² and IL-6, were elevated in the midbrain of LPS- and MPTP-treated neonatal mice. The viability of dopamine (A9) neurons was preserved in neonatal mice of the LPS-MPTP group compared with the MPTP group. In contrast, the viability of these neurons in aged mice dropped significantly. These results may suggest that activated microglia show different phenotypes; i.e., microglia activated by LPS in the neonatal brain may be neuroprotective for dopaminergic neurons in MPTP-treated mice, whereas in aged mice they may be neurotoxic for dopaminergic neurons. The dissociation between injury-induced microglial activation and neuronal degeneration in TNF receptor and colony-stimulating factor 1 (CSF-1) knockout mice suggests that microglial activation is not a determinate event in dopaminergic neuronal damage in brain. Furthermore, there is a growing body of evidence that microglia may play a beneficial role in ischemia by secreting factors (growth factors or cytokines) that promote survival of neurons. Therefore, activated microglia may produce not only neurotoxic effects but also neuroprotective ones, depending upon their environmental
situation.</p>
</sec>
<sec id="Sec43">
<title>Direct Evidence of Neuroprotection by Microglia in theÂ Brain</title>
<p id="Par93">We have reported that exogenous microglia enter the brain parenchyma through the bloodâbrain barrier and migrate to ischemic hippocampal lesions when they are injected into the circulation. By applying this brain-targeted delivery technique, we investigated the effect of exogenous microglia on ischemic pyramidal neurons [<xref ref-type="bibr" rid="CR182">182</xref>]. To this end, we isolated microglia from neonatal mixed brain cultures, labeled them with a fluorescent dye PKH26, and injected them into the artery of Mongolian gerbils subjected to ischemia reperfusion neuronal injury. PKH26-labeled microglia migrated to the ischemic hippocampal lesion and increased the survival of neurons, even when the cells were injected 24Â h after the ischemic insult. Furthermore, stimulation of isolated microglia with IFN-Î³ enhanced the neuroprotective effect on the ischemic neurons.</p>
<p id="Par94">Microglia also protected ischemia-induced learning disability. As migratory microglia increased the expression of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in the ischemic hippocampus, they might induce neurotrophin-dependent protective activity in damaged neurons. These results represent the first experimental demonstration
of neurotrophic effects of microglia on transient global ischemia in vivo. Since peripherally injected microglia exhibit specific affinity for ischemic brain lesions and protect against ischemic neuronal injury in the present model, we suggest that microglia may have the potential to be used as a candidate for cell therapy for CNS repair following transitory global ischemia and other neurodegenerative diseases.</p>
</sec>
<sec id="Sec44">
<title>Toxic Transformation of Microglia by Nef Protein Introduction</title>
<p id="Par95">Nef, a multifunctional HIV
protein, activates the Vav/Rac/p21-activated kinase
(PAK) signaling pathway. Given the potential role of this pathway in the activation of the phagocyte NADPH oxidase, we have investigated the effect of the HIV-1 Nef protein on microglia superoxide production and toxicity for neurons [<xref ref-type="bibr" rid="CR183">183</xref>]. Microglia were transduced with lentiviral expression vectors to produce a high level of Nef protein. Expression of Nef did not activate the NADPH oxidase by itself, but led to a massive enhancement of the responses to a variety of stimuli (Ca2+ ionophore, formyl peptide, endotoxin) and induction to produce a large amount of superoxide. These effects were not caused by upregulation of phagocyte NADPH oxidase subunits. Nef mutants lacking motifs involved in the interaction with plasma membrane and/or other cytosolic proteins failed to reproduce the effects of wild-type Nef, suggesting involvement of a certain signaling pathway in microglia for their trophic-toxic control. Our results suggest a key role for Rac activation in the priming for microglia toxic activation, which is enhanced by Nef introduction in the nontoxic form of microglia. Rac activation is not sufficient to induce the toxic form of microglia accompanied by stimulation of the phagocyte NADPH oxidase; however, it markedly enhances the NADPH oxidase
response to other stimuli and might be involved in the trophic-toxic control
of microglia.</p>
</sec>
<sec id="Sec45">
<title>CNS Cytokine Network</title>
<p id="Par96">
Cytokines
are polypeptidic soluble
factors that control the growth and differentiation of cells involved in immune and hematopoietic systems. These factors were initially considered to act on target cells in a cell-type and stage-specific manner. However, it has been shown that their biological actions are pleiotropic, complementary, and counteractive; each of them exerts multiple effects on different cells, and different factors can act on the same cell populations to induce similar or opposite effects. Moreover, production of several cytokines is controlled by other cytokines in a stimulatory or inhibitory manner, and, in some cases, acts as a cascade. These complex cytokine actions are therefore referred to as a cytokine network.</p>
<p id="Par97">Recent evidence suggests that bidirectional communication occurs between cells of the nervous and immune systems. The basis for this communication is the release of cytokines by immune component cells, as well as hormone products of the neuroendocrine system. Cells resident within the CNS can synthesize, secrete, and respond to inflammatory cytokines not only contributing to the responses to injury or immunological challenge within the CNS but also regulating their own growth and differentiation potential. There are many similarities of cytokine actions between the immune system and the CNS. However, there are also several unique modes of cytokine action in the CNS (i.e., their target cells, inducing functions on the target cells such as other cytokine production, major histocompatibility complex (MHC) antigen induction, and cell growth control, and inducing agents of their production). Therefore, the actions and communication of cytokines in the CNS are designated as the CNS cytokine network [<xref ref-type="bibr" rid="CR184">184</xref>].</p>
<p id="Par98">Microglia are one of the most important cells in the CNS cytokine network. They produce a variety of cytokines, as well as their proliferation and other functions are regulated by cytokines. Astrocytes are another cell population important in the CNS
cytokine network. There are many similar aspects of cytokine production and responses between microglia and astrocytes; however, the roles in the CNS cytokine network may differ between these cells; microglia may have an important function in the removal of dead cells or their remnants by phagocytosis in brain injury, while astrocytes provide structural and environmental support for neurons. There are no clear indications of the difference between the roles of microglia and astrocytes in the cytokine production and response.</p>
<p id="Par99">Some of these cytokines control the growth, differentiation, and activation of cells in the CNS, and some modulate growth factor production, MHC antigen expression, and morphological changes. Their biological functions are mediated by specific receptors, some of which are expressed in the CNS, and cellular localization of cytokine receptors in the CNS
has been demonstrated. Neuronal cells and oligodendrocytes as well as microglia and astrocytes expressed several cytokine receptors indicating that certain functions of these cells may also be controlled by some cytokines. However, to determine the involvement of cytokines in controlling the functions and development of CNS cells requires elucidating the functional relationships of cytokines and these cells.</p>
<p id="Par100">There are two aspects of roles of the CNS cytokine network, one of which is regulation of growth and differentiation of neural cells, and production of cytokines in the CNS. Another aspect of the CNS cytokine network is its interaction with the immune system. Since the majority of cytokines are produced by immune cells, it is possible that immune cells may also control the growth and function of CNS cells. Therefore, the control of microglial growth by cytokines is an important method of regulation of CNS cells by peripheral immune cells. In addition to this, cytokines produced in the CNS can control immune cell functions. These communications may be important for brain-immune interactions, and some aspects may play crucial roles in certain pathological conditions
such as AIDS-dementia complex
and multiple sclerosis as well as several neurological diseases.</p>
</sec>
</body>
</sub-article>
<sub-article article-type="research-article" id="Sec46">
<front-stub>
<title-group>
<article-title>Application of Preclinical PET Imaging for Infectious Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nishi</surname>
<given-names>Kodai</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kudo</surname>
<given-names>Takashi</given-names>
</name>
</contrib>
</contrib-group>
</front-stub>
<body>
<sec id="FPar10">
<title>Abstract</title>
<p id="Par101">PET is a useful imaging tool for basic studies. Preclinical imaging studies such as small-animal PET allow the performance of imaging experiments using the same individuals, without sacrificing the animals. Some researchers who study infectious diseases are thus paying close attention to preclinical imaging techniques. Generally, pathogens are classified by their risk, as the biosafety level (BSL). When conducting research using high-BSL pathogens, special facilities are necessary for pathogen containment. At Nagasaki University, a small-animal imaging system was introduced into BSL-3 section, and various infectious disease imaging studies have been conducted, such as for severe fever with thrombocytopenia syndrome (SFTS), leishmaniasis, and so on. FDG and <sup>67</sup>Ga-citrate are widely used radiotracers for the clinical imaging that can detect inflammation due to infection. For animal imaging, <sup>68</sup>Ga-citrate is a PET tracer that is not yet approved for human imaging, and can be used instead of <sup>67</sup>Ga-citrate, which is single photon emission computed tomography (SPECT) tracer. Even without using special or unorthodox radiotracers, new knowledge and important information can be obtained from preclinical PET studies.</p>
<p id="Par102"><bold>Keywords</bold>:âSmall animal imaging, Preclinical study, Infectious diseases, Biosafety level</p>
</sec>
<sec id="Sec47">
<title>Introduction</title>
<p id="Par103">PET imaging
has recently gained wide use not only in clinical stages but also in basic studies. Small-animal imaging uses the same technology as clinical imaging. Clinical research and problems can thus be introduced to preclinical research directly using small animals. Conversely, applying results obtained from preclinical studies to clinical imaging is also possible. Imaging has bridged the gap between basic studies and clinical research, and has become widely recognized as a tool for translational research.</p>
<p id="Par104">In traditional animal experiments, relatively high numbers of animals are often required. One reason is that animals are sacrificed to remove organs or tissues for the purposes of observation and measurement. Another is the influence of individual differences. In particular, the four elements of pharmacokinetics (absorption, distribution, metabolism, and excretion) are known to be strongly affected by individual differences. The number of samples must therefore be increased for accurate statistical processing.</p>
<p id="Par105">On the other hand, preclinical imaging experiments allow use of the same individual, performing the study and repeatedly acquiring data without killing the individual. This means that applying human imaging techniques to a small animal allows follow-up of changes over time in disease models in the same individual, clarifying changes according to the disease condition more precisely, as in daily practice in the clinical field. In addition, preclinical imaging is an effective technique not only for providing biological information but also for reducing the number of experimental animals.</p>
<p id="Par106">In the area of research into infectious diseases, evaluation of pathogen infection, tracking disease state, and observation over time of individuals are very important, because infectious and inflammatory diseases change with the passage of time. For example, diseases may pass through stages of infection, pathogenesis, ingravescence, remission, and healing. When those stages of infectious disease are studied by sacrificing the animals, the number of animals required to obtain meaningful results will become extremely large due to the large interindividual variance of animals. Small animal PET
imaging has therefore gained attention as a useful experimental method.</p>
</sec>
<sec id="Sec48">
<title>Imaging Laboratory for Infectious Diseases</title>
<p id="Par107">To conduct imaging studies
using infected model animals, a special laboratory is required. This is because researchers must be protected not only from radiation exposure but also from the risk of infection. Biosafety level (BSL) is a classification depending on the degree of pathogen risk. Table <xref ref-type="table" rid="Tab2">1.2</xref> shows representative pathogens sorted by BSL from the guidelines of the National Institute of Infectious Disease (NIID).<table-wrap id="Tab2"><label>Table 1.2</label><caption><p>
BSL classification of representative pathogens</p></caption><table frame="hsides" rules="groups"><thead><tr><th>BSL</th><th>Virus</th><th>Bacteria</th><th>Fungi</th><th>Parasitic insect</th></tr></thead><tbody><tr><td rowspan="4">2</td><td><italic>Dengue virus</italic>
</td><td><italic>C. botulinum</italic>
</td><td><italic>Aspergillus fumigatus</italic>
</td><td><italic>Balantidium coli</italic>
</td></tr><tr><td><italic>Hepatitis C virus</italic>
</td><td><italic>C. jejuni, coli</italic>
</td><td><italic>Candida albicans</italic>
</td><td><italic>Leishmania</italic>
</td></tr><tr><td><italic>Norovirus</italic>
</td><td><italic>E. coli</italic>
</td><td><italic>Cryptococcus neoformans</italic>
</td><td><italic>Echinococcus</italic>
</td></tr><tr><td><italic>Papillomavirus</italic>
</td><td><italic>H. pylori</italic>
</td><td></td><td><italic>Anisakinae</italic>
</td></tr><tr><td rowspan="4">3</td><td><italic>SARS corona virus</italic>
</td><td><italic>F. tularensis</italic>
</td><td><italic>Blastomyces dermatitidis</italic>
</td><td rowspan="4">N/A</td></tr><tr><td><italic>West-Nile virus</italic>
</td><td><italic>M. tuberculosis</italic>
</td><td><italic>Histoplasma capsulatum</italic>
</td></tr><tr><td><italic>SFTS virus</italic>
</td><td><italic>S. enterica</italic>
</td><td><italic>Penicillium marneffei</italic>
</td></tr><tr><td><italic>New York virus</italic>
</td><td><italic>R. japonica</italic>
</td><td></td></tr><tr><td rowspan="3">4</td><td><italic>Lassa</italic>
</td><td rowspan="3">N/A</td><td rowspan="3">N/A</td><td rowspan="3">N/A</td></tr><tr><td><italic>Ebola</italic>
</td></tr><tr><td><italic>Marburg</italic>
</td></tr></tbody></table></table-wrap>
</p>
<p id="Par108">When dealing with high-risk pathogens, researchers need to use a biocontainment laboratory conforming to the World Health Organization (WHO) guidelines. When using imaging systems, measures must also be taken to avoid contamination by biohazards, such as installation in separated safety rooms, prevention of cross-contamination using sealed animal tubes, and so on [<xref ref-type="bibr" rid="CR185">185</xref>]. In addition, researchers need to wear a Tyvek coverall, mask, rubber gloves and face guard (Fig. <xref ref-type="fig" rid="Fig29">1.29</xref>). Given the restrictions as described above, only limited numbers of facilities around the world are capable of performing imaging studies for infectious diseases, and relatively few studies
have been conducted.<fig id="Fig29"><label>Fig. 1.29</label><caption><p>An example of using protective clothing to prevent exposure of the skin and cover the face completely with the face guard</p></caption><graphic id="MO29" xlink:href="477582_1_En_1_Fig29_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec49">
<title>PET Imaging with Infectious Small Animals</title>
<p id="Par109">In 2012, a small-animal imaging system was introduced to the BSL-3
section of the radioisotope center at Nagasaki University, making this the only facility in which researchers could perform imaging of infectious diseases requiring a high BSL in Japan. Since then, various infectious diseases imaging studies have been conducted.</p>
<p id="Par110">Hayasaka et al. reported an FDG-PET study using mice infected with severe fever with thrombocytopenia syndrome (SFTS) virus, which is categorized as BSL-3. SFTS is a tick-borne infection that causes severe inflammation in the gastrointestinal tract [<xref ref-type="bibr" rid="CR186">186</xref>]. In that study, SFTSV-infected mice were administered about 10 MBq of FDG intravenously via the tail vain. PET acquisition was performed for 30 min from 30 min after FDG injection. FDG uptake was found along the course of the intestine in the SFTS-infected mouse (Fig. <xref ref-type="fig" rid="Fig30">1.30</xref>) [<xref ref-type="bibr" rid="CR187">187</xref>].<fig id="Fig30"><label>Fig. 1.30</label><caption><p>FDG-PET/CT images of mice with or without SFTSV infection. In the mock-infected mouse, FDG accumulation is observed in the heart and bladder. On the other hand, in the SFTSV-infected mouse, FDG accumulates in the gastrointestinal tract (yellow arrow)</p></caption><graphic id="MO30" xlink:href="477582_1_En_1_Fig30_HTML"></graphic></fig>
</p>
<p id="Par111">PET studies on SFTS have also been performed using <sup>68</sup>Ga tracer. Fuchigami et al. tried to visualize SFTS with <sup>68</sup>Ga-citrate [<xref ref-type="bibr" rid="CR188">188</xref>]. Generally, <sup>67</sup>Ga-citrate is a radiotracer used for single-photon computed tomography (SPECT), and is widely used to detect tumors [<xref ref-type="bibr" rid="CR189">189</xref>, <xref ref-type="bibr" rid="CR190">190</xref>], inflammation, and infectious diseases [<xref ref-type="bibr" rid="CR190">190</xref>, <xref ref-type="bibr" rid="CR191">191</xref>]. Since <sup>68</sup>Ga-citrate is a PET tracer behaving exactly the same as <sup>67</sup>Ga-citrate, targets can be imaged quantitatively and with higher sensitivity. In that study, SFTSV-infected mice were administered about 5 MBq of <sup>68</sup>Ga-citrate intravenously via the tail vain. PET acquisition was performed for 1Â h, starting 2Â h after <sup>68</sup>Ga-citrate injection. As shown in Fig. <xref ref-type="fig" rid="Fig31">1.31</xref>, high accumulation of <sup>68</sup>Ga-citrate in the gastrointestinal tract was observed in SFTSV-infected mice, and the accumulation pattern of <sup>68</sup>Ga-citrate resembled that of FDG.<fig id="Fig31"><label>Fig. 1.31</label><caption><p>Images from <sup>68</sup>Ga-citrate (<bold>a</bold>) and FDG (<bold>b</bold>) PET/CT of SFTSV-infected and mock-infected mice. Yellow arrows indicate the gastrointestinal tract</p></caption><graphic id="MO31" xlink:href="477582_1_En_1_Fig31_HTML"></graphic></fig>
</p>
<p id="Par112">In addition, <sup>68</sup>Ga-citrate was used for PET imaging of leishmaniasis [<xref ref-type="bibr" rid="CR188">188</xref>]. Leishmaniasis is a tropical disease caused by <italic>Leishmania</italic> parasites categorized as BSL-2, and <italic>Leishmania</italic> leads to strong localized inflammation [<xref ref-type="bibr" rid="CR192">192</xref>]. <italic>Leishmania</italic> parasite-infected mice were administered about 4 MBq of <sup>68</sup>Ga-citrate intravenously via the tail vein. PET acquisition was performed for 1Â h, starting 2Â h after <sup>68</sup>Ga-citrate injection. As shown in Fig. <xref ref-type="fig" rid="Fig32">1.32</xref>, inflammation site-specific accumulation of <sup>68</sup>Ga-citrate was observed [<xref ref-type="bibr" rid="CR188">188</xref>].<fig id="Fig32"><label>Fig. 1.32</label><caption><p>PET/CT images of footpad regions in <italic>L. major</italic>-infected mice. A signal from the <sup>68</sup>Ga-citrate is observed at a site in the left leg (yellow arrows), with no signal in the contralateral leg (blue arrows)</p></caption><graphic id="MO32" xlink:href="477582_1_En_1_Fig32_HTML"></graphic></fig>
</p>
<p id="Par113">The examples given here are only a small selection of many studies underway at Nagasaki University. Infectious disease studies are more diverse
than tumor studies, because infectious diseases have numerous diseases classified as tropical infections and emerging infectious diseases, and many issues have not been elucidated for each disease. FDG and <sup>68</sup>Ga-citrate used in the studies introduced this section are widely used general radiotracers that are easily obtained. Even without using special or unorthodox radiotracers, new knowledge can be obtained from preclinical PET studies.</p>
<p id="Par114">The pathological condition of the infected animal will change depending on species differences and the infected pathogen. Some models only have about 3Â days between infection and death. When conducting imaging research into infectious diseases, investigation of the survival rate of model animals as a preliminary experiment and preparation of a survival curve is desirable. Also, breeding of model animals requires prevention of infection with other infectious diseases. Experiments using infected animals thus require some additional caution, as previously mentioned.</p>
<p id="Par115">In conclusion, small animal imaging using preclinical PET
bridges the gap between basic researches and clinical practices and works as an important tool for translational research in infectious disease.</p>
<sec id="FPar11">
<title>Acknowledgement</title>
<p id="Par116">The authors are grateful to the American Chemical Society (ACS) for allowing reuse of some images (Figs. <xref ref-type="fig" rid="Fig31">1.31</xref> and <xref ref-type="fig" rid="Fig32">1.32</xref>) and a direct link to the ACS article: <ext-link ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/abs/10.1021/acsomega.7b00147">https://pubs.acs.org/doi/abs/10.1021/acsomega.7b00147</ext-link>.</p>
</sec>
</sec>
</body>
</sub-article>
</article>
</pmc-articleset>